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INTRODUCTION 
 
                Siddha system of medicine is one of the traditional system of medicine 
particularly in the regions of south India. Treatment and diagnosis in siddha system of 
medicine is based on three dosa. Any variation in three dosas results in disease. This 
proved with reference from 
 
                “kpfpDk; FiwapDk; Neha;nra;Ak; E}Nyhh; 
        tspKjyh vz;zpa %d;W” 
                                                                               - jpUf;Fws; 
 
    In general, Siddhars contributed wonderful medicines which are in consonance 
with the composition of the body. 
 
       The World Health Organization (WHO) has estimated that globally, 1.62 billion 
people are pandu, with the highest prevalence of pandu (47.4%) among preschool – 
aged children. Of these 293 million children, 89 million live in India. According to the 
third National Family Health Survey (NFHS) 2005-2006 revealed that at least 80% of 
Indian children were pandu. 
 
             Today in our country, Pandu is one of the major problem in paediatrics. It mostly 
affects cell growth and proliferation in tissues like nervous system and gastro intestinal 
tract. 
 
               In India because of poverty, poor socio-economic pattern, malnutrition, 
untreated illness, hook worm infestation is the common cause of Pandu noi among the 
pre-school and school going children. 
 
          Kuzhanthai maruthuvam is a specialized branch in Siddha medicine which deals 
with the treatment of the disease of children upto 12 years. The diseases in children are 
broadly classified in two categories – Ahakarana noigal(diseases that occurs in the 
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intrauterine period) and the Purakarana noigal(diseases that occurs after child‟s birth ie., 
due to intrinsic causes) 
 
In siddha system “PANDU NOI” is equivalent to “ANAEMIA”. 
     National anemia controlling programs aims at significantly decreasing the 
prevalence and incidence of anemia in preschool children and adolescents. Even though 
anemia is one of the major public health problems in developing India. 
 
            In order to treat this, a safest, highly efficacy and cost effective drug is needed. 
That is safe drug “Pandu noikku kalappu thool” has been choose by the author.  
  
   Pandu noikku kalappu thool is a multi compound herbal drug has the trail drug 
through a literature review of modern and siddha texts, biochemical, pharmacological and 
clinical trial were carried out and the result obtained were discussed in the end. 
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AIM AND OBJECTIVES 
AIM  
Prevention and cure are basic aims in Siddha system of medicine, which prevent 
disease by careful dieting and proper relaxation of the mind to achieve a totality of health. 
 
    India being densely populated with people of different socio-economic status, 
children with poor sanitary facilities, lack of personal and environmental hygiene are the 
common victims of this disease. It forms one of the major causes of sickness among 
children which causes a heavy economic burden to health services. They have been 
suffering from various diseases due to deficiency of nutrition 
 
    It is essential to find out a simple drug to treat this disease. The drug should be 
easily available, economic, easily administered and also highly effective in smaller doses.  
  As a Siddha pediatrician, an extra personal interest in the study of new drug for 
this common nutritional deficiency has been aimed. With this aim in mind, Pandu 
Noikku Kalappu Thool was tried in the patients suffering from Pandu. 
 
OBJECTIVES 
1. To collect the literature evidence regarding the disease “Pandu” 
 
2. To analyze the trial medicine in bio-chemically and pharmacologically for 
complete evaluation of the drug. 
 
3. To have a clinical trial on Pandu noi in children with a selected medicine viz., 
“Pandu noikku kalappu thool” with honey. 
 
4. To have an idea about prevalence of Pandu Noi with reference to Age, Sex, 
Socio-economic status, Seasonal variations, Poverty, etc., 
 
5. To evaluate the disease Pandu clinically by careful examination on etiology, 
clinical features, treatment, prognosis, complications, etc., 
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6. To know the extend of correlation of etiology, classification, symptomatology, 
diagnostic methods and line of treatment compared with more or less anemia in 
the modern aspects. 
 
7.  To have a complete study of the disease Pandu under the headings of 
Mukkutram, Udalkattugal, Envagai thervugal, Neerkuri, Neikuri etc., in order to 
evaluate the pathogenesis pathology of Pandu. 
 
8. To make use of modern parameters in the investigation side to confirm the 
diagnosis and to follow the progress of patients. 
 
9. To make an awareness among the parents about the prevention of the disease in 
children. 
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REVIEW OF LITERATURE 
SIDDHA ASPECT 
ghz;L Neha; 
NtW ngah;fs; 
         ntSg;G Neha;> ntz;ik Neha;> ntz;ghz;lk; 
 
,ay;: 
       ,aw;if epwk; khwp cly; ntSj;J fz;izAk; eff; fz;izAk; ePf;fpg; 
ghh;f;fpd; FUjpapd;wp ntSj;jpUf;Fk;. 
- Neha; ehly; Neha;Kjy; ehly; gFjp – 2 
-  
        Njfj;jpd; ,uj;jj;jpy; cs;s rpte;j mZf;fs; Fiwe;J Njfk; ntSj;J 
tpLtjw;F ghz;LNeha; vd;Wngah;. 
 
         ghz;LNeha; ,uj;jk; nfl;L gythuhd Neha; Nrh;tjhy; cz;lhfpwJ. 
- Mj;kul;rhkph;jk; gf;fk; 522 
-  
        moy;Fw;wk; kpFe;J gpj;jj;jpd; tiffshd mdw;gpj;jk; kw;Wk; 
,uQ;rfgpj;jk; ,tw;iwf; Nflila nra;J FUjpapd; epwj;ijAk; viliaAk; 
nfLj;J clYf;F Ntz;ba Cl;lj;ijAk; nfhlhky; cliy ntSf;fr; nra;Ak; 
Neha;. 
 
“fopthFe; Njfkg;gh fhzj;j rtj;jha; 
tw;wptpL kd;dthry; Nfl;fpy; 
gopfhuh; Kfj;jpdpy; Kopahh; NghNy  
ghz;lnky;yhk; ntSf;fbj;jJ uj;jk;” 
                                   -mfj;jpah; itj;a fhtpak;. 
 
       “Njfj;jpy; ,uj;jk; tw;wp 
        jPq;fhd tpe;j Neha; fhZkg;gh” 
                                  -mfj;jpah; Fzthflk; 
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         ghz;LNuhfkhdJ khh;G mjpuy;> rhPuk;  mNuhrpfk;> kQ;rs; epwkhd rpWePh;> 
tpah;it> ke;jhf;fpdp> Njfk; ,isj;jy;> ntSj;jy;> Mahrk; vd;Dk; 
,f;Fzq;fisj; jdf;F ,ay;ghfg; ngw;wpUf;fpd;wd. 
- rpfpr;rh uj;d jPgk; 
Neha; tUk; top 
         nghJthf tsh; ,sk; Foe;ijfs;FUjpapd; td;ikiaf; Fiwf;ff; $ba 
cg;G Gspg;Gs;s nghUl;fis kpFjpahff; nfhs;tjhYk;> Ruk;> Ngjp> the;jp> 
fPo;thA Kjypa Neha;fSf;Fl;gLtjhYk;> FUjpia msT fle;J ntspahf;Fk; 
FUjpaoy; Neha;> FUjp fopr;ry>; KisNeha;> FUjpthe;jp Kjypait 
Vw;gLtjhYk; ntl;Lg;gl;L kpFjpahff; FUjp ntspg;gLjyhYk; ,e;Neha; 
cz;lhk;. md;wpAk; er;Rj;jd;ikAila kUe;Jfis ehssTf;F kpQ;rp 
cz;gjhYk;> cliy ,isf;fr; nra;Ak; tapw;WGONeha;> ,isg;GNeha;> 
epzf;fopr;ry; KjypaitfshYk; FUjpngUf;iff; nfLf;ff;$ba <uy; 
Neha;fshYk;> Gifapiy> ntw;wpiyg;ghf;F> kz;> rhk;gy>; jpUePW> fw;G+uk; 
Kjypaitfis mbf;fb nfhs;tjhYk; ghz;LNeha; tUk;. 
- Neha; ehb Neha; Kjy; ehly; gFjp -2 
-  
          “gpwe;jehs; gps;isf;Fj; jhNd ed;wha; 
            gpjhthNy gpzpAlypd; NkNy Njhd;Wk;” 
         “tpidaJ tUFNeh;ik tpgukh Aiuf;ff;Nfsha; 
           midaJ thfe;jhD kghddhk; thA$b 
          GidaJ fPo;Kyj;jpw; Gf;fpdhy; jbf;Fk; Njfk; 
           fdyJ nkj ;jf;fhZk; fz;zJ ntSf;Fe;jhNd” 
- ghythflk; 
         ‘fUjpa kPdpd; Ks;Sk; fye;Jkp nea;apy; thYk; 
          kUtpa vYk;Gq; fy;Yk; kq;ifah; kUe;jPLk; 
          gofpa goQ;Nrhw;whYk; goky epiwifahYk; 
          kUfpa kaph;fshYk; te;jpLk; NehajhNk 
          Gwtiu Az;ifahYk; Nghf ePUz;ifahYk; 
          RusNt Klf;fpf; nfhz;L Kwf;fplf;ifahYk; 
          ngUf ntz;nlhopapdhYk; gpwf;fNehnad;Nw fhNz” 
                                                                    - Njiuah; thflk; 
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Njiuah; thflj;jpd; $w;Wg;gb kPd; Ks;spdhYk; > Kb> vd;G> fs;> 
gioaNrhW>  khRgbe;j FbePh;> jtwhd Kiwapy; cwf;fk; nfhs;tjhYk; ghz;L 
Neha; cz;lhfpwJ. 
            “ehnkd;w nrhy;YfpNwhk; ghz;L te;j 
              eykhd fUkkJ nrhy;yf; NfS 
             jhnkd;w jha;je;ij kdk;Nehfr; nra;jhy; 
              juzpjdp Ys;s thf;Fk; md;Ng nrhy;y 
             thnkd;w tpUg;gopj;jy; nrtp Rthr 
              kw;Wk; ngha; nrhy;yyhq; fhuQ; nra;jy; 
             Ntnkd;w fUkkJ gpj;jNkwp 
              ntWj;jjlh ntg;G kpQ;rpf; iffhNyha;Nt” 
                          -mfj;jpah; thflk; 
 
mfj;jpah; thflj;jpd; $w;Wg;gb ngw;Nwhhpd; Ngr;ir kjpf;fhkYk; ngha; 
NgrpdhYk; Nfhgg;gLtjpdhYk; clypy; gpj;jk; mjpfhpf;Fk; cly; Nrhh;T 
Vw;gLk;. 
            “jpUe;jpLk; ghz;L Nuhfq; Nrh;e;jpLq; Fzj;ijf; Nfsha; 
                  ,Uj;jpLk; thj gpj;jr; rpNyw;gd kpitjhd; khWk; 
             ghpe;Jjh ndhd;Nwh nlhd;W nghUe;JtjhY kz;NzhL 
                  mUe;JtjhYk; ghz;L mize;jpL nkd;dyhNk 
             Mfpa %ye;jd;dp yize;j Tl;lzj;jpdhYe; 
                   Njhifah; Nkfj;jhUk; Jah;kpF Nrh;jyhYk; 
             NjfNghridAs;shh;f;Fj; jhpj;jpuQ; Nrh;jyhYk; 
                    Ntfkhe;jphpNjhUq;fs; kpQ;rpNa ghz;LthNk” 
                                           - jd;te;jphp itj;jpak; 
 
jd;te;jphp itj;jpak; $w;Wg;gb Kf;Fw;wq;fspd; khWghl;lhYk; kz; 
Kjypaitfis cz;gjhYk; ghz;L Neha; czlhfpd;wd. 
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               “nrhy;yhj fbtp~q;fs; Fd;kk; ghz;L 
                     Jah;jPuhf; fdktpid nra;j ghtk; 
                vy;NyhUk; eiff;f cLk;ngLj;j ghtp 
                      ,d;dKz;L tpgukha; cyfpw; NfNs.” 
                       -mfj;jpah; ghpG+uzk; - 400 
  
mfj;jpah;  ghpG+uzk;-400 $w;Wg;gb ghz;L fd;ktpidahYk; cz;lhfpd;wJ.  
           
guje;jpu fhuzq;fspdhy; ghz;L cz;lhFk; vd ruNge;jpu itj;jpa 
Kiwfs; ghz;L fhkhiy rpfpr;ir E}y; $wpAs;sJ. 
              “tay;jdpNy G+ehf kz;izj; jhNd 
               tUe;jpaJ Gj;J Nghy tj;ijahFk; 
               gapy; nkhopaPh; Njfj;jpy; fpUkpjhNd” 
                                                             -FUehb 
 
FUehb $w;Wg;gb fpUkpahy; ghz;L Neha; cz;lhfpwJ. 
 
             “FwpQ;rptU epyj;jpw; nfhw;w Kz;b uj;jk; 
                   cwpQ;rptU RuKz;lhk; mwpQUiuf; 
              ifaNk jq;Fjuj; jhik ty;iyAq; fjpf;Fk; 
                    IaNk jq;Fk; mwp” 
                                                         -gjhh;j;j Fz rpe;jhkzp 
 
FwpQ;rp epyj;jpy; trpg;gtUf;F ghz;L Neha; cz;lhFk; vd gjhh;j;j Fz 
rpe;jhkzp $WfpwJ. 
 
ghz;L Neha; FwpFzq;fs; 
          mjpfkhd cly;Nrhh;T> %r;Rtpl rpukk;> fz; ghh;it> xspFd;wy;> 
kaf;fk;> khh;G glglg;G> cly; ntSj;jy; cz;lhFk;. 
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nghJ FwpFzq;fs; 
         ,e;Nehapy; cly; td;ik ehSf;F ehs; Fiwe;J elf;f ,ayhik> 
jiyNehjy;> kaf;fKz;lhjy;> %r;Rj;jLkhwy;> grpj;jPf;nfly;> czT 
Ntz;lhik> cz;l rpW czTk; the;jpahjy; Mfpa Fwpfs; Njhd;Wk;. ,d;Dk; 
kpfTk; ntSj;Jj; Njhy; RUq;fy;> cly; nkype;J gsgsj;J ntSg;ghjy;> eff; 
fZf;fs; jbj;J ntSj;jy;> ehntbj;J Gz;zhjy; my;yJ ehtpd; 
Nky;Njhiyr; rPtpnaLj;jJ Nghd;W rpte;J fhZjy; njhz;ilf; fl;ly; vd;Dk; 
FwpfSk; fhDk;. 
                                                                         -A+fp itj;jpa rpe;jhkzp 
             
‘nrlkJ gpj;j ePuhy; njspj;jjhy; Njf nkq;Fk; 
              flkJ fdf;f T+jpf; fz;ZNk ntSf;Fe; jhNd 
             ntSj;jpL kpuz;lhz; lhdhy; tpidao #of; Nfsha; 
              fisj;jpL rlye; jd;dpy; fdyjha; twl;rp fhZk; 
             gOj;jpLe; Njf %jpg; ghz;L Nghyhk;” 
                                                                          -ghythflk; 
 
ghythflj;jpd; $w;Wg;gb fz; nts;tpop ntSj;jy;> cly; twl;rp>  cly;Nrhh;T> 
tPf;fk; cz;lhFk;. 
            “cw;wNjhh; md;dNgjk; mNuhrfk; Kjuke;jk; 
              Kw;wpkhh;G Neha; %j;jpuk; nghd;dpd; td;ik 
             nts;spNrh; Gwq;fhy; iftPf;fKly; ntSj;jy; 
            Nth;j;jy;gw;wp njhf;fpw;fha; gzpj;jpa ghz;LthNk” 
                                                           -mfj;jpah; itj;jpa uj;jpdr;RUf;fk; 
 
mfj;jpah; itj;jpa uj;jpdr; RUf;ff; $w;Wg;gb grpapd;ik> khh;Gtyp> rpWePh; epwk; 
khw;wk;> fZf;fhy; tPf;fk;> fz; ,iug;ig tPq;fy;> cly; ntSj;jy; cz;lhFk;. 
          rUk ntbg;G> mbf;fb fhwp ckpo;jy;> Njfk; nkypjy;> kz; rhg;gpLtjpy; 
tpUg;gk;> fz;fisr; Rw;wpYk; tPf;fk;> kyk; %j;jpuk; Kjypaitfs; kQ;rs; 
epwkiljy;> rhg;ghL ed;whfr; nrhpahik Kjyhd Fwpfs; Vw;gLk;. 
-ruNge;jpuh; itj;jpa Kiwfs;. 
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             ‘cz;lhFk; Ntisjd;dpy; NjfNeh;ik 
                   cWjpahar; nrhy;YfpNwd; ed;wha; ghU 
              Fz;lhd Kfk; fz;fs; cjL ehf;F 
                    Fwpg;ghd tha; NtFk; Njf Kw;Wk; 
              Ntz;lhf NtAyh;e;J ntz;ikahfp 
                    tpuy; efq;fs; KOtjpYk; uj;jk; tw;wp 
              fz;lhd fhy;fs; jhd; jzpe;J epw;Fk; 
                     fUthd ehbaJ nkJtha;g; NghNk 
              NghNkjhd; jPgdq;fs; kl;Lg;gl;L 
                    nghypthd fz;topfs; ngUj;Jj; Njhd;Wk; 
              Mnkjhd; mrf;jpA khahrq; fz;L 
                     mth; eilAk; jsh;e;J ngU%r;Rf; fz;L 
              %Nkjhd; %h;r;irAld; khh;Jbj;J 
                     Kbthd fZf;fhypy; tPf;fKz;lha; 
               J}Nk jhdpUjaj;jpd; tjde; jd;dpw; 
                      JUj;jp epfh; rj;jkJ Nfl;Fk;ghNu”. 
                                                              -mfj;jpah; Fzthflk;. 
mfj;jpah; Fzthflj;jpd; $w;Wg;gb Njhy; twl;rp> Kfk; fz; ehf;F 
eff;fz; ntSj;jy;> cly;Nrhh;T> ehbeilFiwT> grpapd;ik> fz; ,iug;ig 
tPq;fy;> khh;G glglg;G> %l;L tPq;fy; cz;lhFk;. 
 
ghz;L Nehapd; tiffs; 
      rpj;j kUj;Jt E}y;fspd; mbg;gilapy; ghz;L Nehapd; tiffs; gythwhf 
tifg;gLj;jg;gLfpwJ. 
 A+fp rpe;jhkzp 800  
 thjg;ghz;L 
 gpj;jg;ghz;L 
 fgg;ghz;L 
 Kf;Fw;wg;ghz;L 
 tplg;ghz;L 
 kz;Zd; ghz;L 
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 b.tp.rhk;grptk;gps;is - 6 
 thjg;ghz;L 
 gpj;jg;ghz;L 
 fgg;ghz;L 
 Kf;Fw;wg;ghz;L 
 CJ ghz;L 
 ePh;g; ghz;L 
 
 kjiy Neha; - 5 
 thjg; ghz;L  
 gpj;jg; ghz;L 
 rpNyw;gd ghz;L 
 ,uj;jg; ghz;L 
 mrhj;jpag; ghz;L 
 
 [Pt uf;rhkpUjk; - 5 
 thjg; ghz;L 
 gpj;jg; ghz;L 
 fgg; ghz;L 
 jphpNjh~g; ghz;L 
 kpUjpfhg;Gf;jg; ghz;L 
 
 Nuhf eph;za rhuk; - 5 
 thjg; ghz;L 
 gpj;jg;ghz;L 
 fgg; ghz;L 
 Kf;Fw;wg; ghz;L 
 tplg; ghz;L 
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 itj;jpa rhu rq;fpufk; - 5 
 thjg; ghz;L 
 gpj;jg; ghz;L 
 %yg; ghz;L 
 %ygpj;jg; ghz;L 
 tplg; ghz;L 
          
 mfj;jpah; Fzthflk; - 5 
 thjg; ghz;L 
 gpj;jg; ghz;L 
 fgg; ghz;L 
 Kf;Fw;wg; ghz;L 
 tplg; ghz;L 
 
 jd;te;jphp itj;jpak; - 7 
 thjg; ghz;L 
 gpj;jg;ghz;L 
 fgg; ghz;L 
 Kf;Fw;wg; ghz;L 
 gpj;jthjg; ghz;L 
 rd;dpthjg; ghz;L 
 igj;jpag; ghz;L 
 
 guuhrNrfuk; - 5 
 thjg; ghz;L 
 gpj;jg;ghz;L 
 fgg; ghz;L 
 rd;dpg; ghz;L 
 kpUjpfhg;Gf;jg; ghz;L 
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 mDNghf itj;jpa Njt ufrpak; - 6 
 thjg; ghz;L 
 gpj;jg;ghz;L 
 fgg; ghz;L 
 Kf;Fw;wg; ghz;L 
 tplg; ghz;L 
 kpUjpfhg; ghz;L 
           
 rpfpr;rhuj;d jPgk; - 5 
 thjg; ghz;L 
 gpj;jg; ghz;L 
 rpNyj;Jkg; ghz;L 
 jphpNjh~g; ghz;L 
 tp~g;ghz;L 
 
 ruNge;jpu itj;jpa Kiwfs; ghz;L fhkhiy rpfpr;ir  - 5 
 thjg; ghz;L 
 gpj;jg; ghz;L 
 fgg; ghz;L 
 re;epghjg; ghz;LNuhfk; 
 kz; jpd;wjhNyw;gl;l ghz;L 
 
ghz;L Nehapd; FwpFzq;fs; 
rpjk;gu jhZg;gps;is mth;fshy; ,aw;wg;gl;l E}ypy; Foe;ijfspy; 
cz;lhFk; ghz;L Nuhfk; kpfr;rpwg;ghf vLj;jpak;gg;gLfpwJ. mjd; tptuk; 
tUkhW> 
thjg; ghz;L 
         “ntSj;Jg;Nghk; thjnkDk; ghz;LjhDk; 
                ntspwpaq;fk; nghs;sYz;lha; jkU tPOk; 
           fOj;jpd; fPo; Nja;e;J ff;fypUky; fhl;Lk; 
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                fz; ntSj;J fWg;ghf nuj;jk; tPOk; 
           gOj;j gok;Nghy; gJq;Fk; cjuk;fz;lha; 
                ghh;j;jpLfpy; gsgsntd kpd;dpf; fhDk; 
           nrGj;jpLk; NrhiyFapy; kapNy Nfsha; 
                Nrjq;fs; thuhJ jpwkha;r; nra;Na” 
 
          cly; ntSj;jy;> fz; fU epwkiljy;> Njhy; gsgsg;giljy; Mfpa 
FwpFzq;fs; thjg; ghz;L Nehapy; fhzg;gLk;. 
 
gpj;jg; ghz;L 
            “njhg;GSk; tapUk; js;sp Fly;jd;dpy; Cw;w Kz;lha; 
             jg;gpis Nghy; jpuz;L rhPuTk; ntSg;Ng NaWk; 
             ikg;GWk; FoypdhNy thAyh;e;jpUf;Fk; fz;lha; 
             ,g;gb Fzq;fs; fz;lhy; gpj;jgris ghz;Nl”. 
 
        gpj;jg; ghz;Ltpy; tapW Cjy;> nfhg;Gs; tPf;fk;>  Fly; tPf;fk; > Njhy; 
twl;rp fhZk; 
 
rpNyw;gdg; ghz;L 
           ‘Gf;fpLk; Nrw;gghz;L nghUe;jpa FzNk jd;dpy; 
            ff;fpLk; nuj;jk; NghNy fz;ntSg;ghFk; Nkdp 
            rpf;fpLk; rpWePh; Ngjp rpWfNt nfz;ilg; gw;wp 
            Nghf;fpLk; njhg;gs;Rw;wp nghUe;jpa RliyNrUk;” 
 
     rpNyw;gd ghz;L Nehapy; FUjpthe;jp> fz; nts;tpop kw;Wk; cly; 
ntSj;jy;> rpWePh;f;fl;L> kyf;fl;L> ce;jpapy; ePh; Nrh;jy; cz;lhfp kuzk; 
Vw;gLk;. 
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uf;jg; ghz;L 
            “rhUNk nuj;j ghz;L rhPuj;ij RUf;fp NkYk; 
             CUNk mq;fnky;yhk; czh;e;jpLk; cjuk; tpk;Kk; 
             fhWnk %f;fpy; nuj;jk; fz;kQ;rs; epwNk 
             MUNkh mwpe;jplhky; ma;Nopy; kuzkhNk” 
 
      uf;jg; ghz;L Nehapy; cly; vil Fiwjy;> mhpg;G> FUjpthe;jp> fz; kQ;rs; 
epwkhf khwp 5 Kjy; 7 ehl;fspy; kuzk; Vw;gLk;. 
 
kz;Zz;  ntSg;G Neha; 
         rpW Foe;ijfSk; rpW tajpdUk;  kz; rhk;gy; nrq;fy; jpUePW fw;G+uk; 
,tw;wpd; kPJ jdpj;j ,r;irf; nfhz;L msT fle;J cz;gjhy; fhZk; 
NehahFk;. cl;nfhz;l nghUSf;F Vw;g tapW Cjy;>  nrhpahik > the;jp> 
fopr;ry;>Ruk; >tapw;Wg;GO Kjypa Neha;fs; fz;L nkype;J FUjp tw;wp ntSj;J 
tPq;fp khh;G Jbj;jy; Kjypa FwpFzq;fisf; fhl;Lk;. 
 
mrhj;jpa ghz;L 
          ‘MWNk mrhj;jpaghz;L mq;fKk; ntSg;gjhfp 
           rPWNk njhz;ilf;Fs;Ns rpy;ypl;lilj;jhg; NghNy 
           ehWNk Njfnkq;Fk; eLf;fpLk; cjuk; tw;wp 
           ghWNk gjpNdohk; ehs; gfh;e;j ey;ypisg; Gz;lhNk”. 
          “,isj;jpLk; fhWG+wha; ,UkYk; %r;Rk; Kl;b  
           fisj;jpLk; ifAk; fhYk; fz;zJ %bf; nfhs;Sk; 
           jisj;jpLk; ghyh;f;F rjpaJ thuhnjd;W 
           tpisj;jpLk; kapNy Nfsha;”. 
 
       mrhj;jpa ghz;L Nehapy; cly; ntSg;G> njhz;ilf; Fspuy;>  cly; 
eLf;fk>; nfl;l ehw;wk;> %r;R jpzwy; Vw;gl;L 17 ehspy; kuzk; Vw;gLk;. 
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ghz;L - njhlh; Neha; 
       ghz;L Nehapy; fgk; mjpfhpj;jhy; Nrhig Njhd;Wk;. gpj;jk; NkYk; 
mjpfhpj;J kQ;rs; fhkhiy Neha; Vw;gLk;. 
         “tpsk;gNt ghz;L Kw;wpUf;Fk; NghJ 
          kPwpNa gpj;j t];Jjidg; Grpj;jhy; 
          G+z;bLNk fhkhiy nad;Dk; Nuhfk;” 
     -A+fpKdp 
 
Kf;Fw;w NtWghLfs; 
    Kd;G Neha; tUk; topapy; $wpathW cly; td;ik Fiwe;J grPj;jP 
(mdw;gpj;jk;) Nflile;J cz;l czT rhpahfr; nrhpahkw; NghFk;.  
 
cztpd; Nfl;lhy; ,ur FUjpfSf;F Cl;lk; ngwhJ. (,uQ;rfgpj;jk;) 
 
NjhYf;F epwj;ijf; nfhLf;Fk; moy; nkype;J epwj;jpYk; vilapYk; 
Fiwe;J jPf;Fw;wj;ijg; ngUf;Fk;. (gpuhrfgpj;jk;) 
 
mjdsthf kw;iwa Fw;wq;fSk; jd;dpiyapy; jphpe;J guTfhypd; td;ikiaf; 
nfLj;J Nehia cz;lhf;Fk;. (tpahdd; ghjpg;gilfpwJ) 
 
Nehapd; td;ik ngUf ngUf IaKk; ngUfp tPf;fk; KjypaitfisAk; 
Jiznfhs;sr; nra;Ak;. 
 
thjk; 
thjk; thOkplk; 
          mghdk;> kyk;> ce;jpapd; fPo; %yk;> Njhy;> euk;Gf;$l;lk;> Cd;> 
gf;Fthrak;> fhJ. 
 
,aw;ifg;gz;G 
1. Cf;fKz;lhf;fy; 
2. %r;Rtply; thq;fy; 
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3. kdnkhop nka;fSf;Fr; nraiyj;juy; 
4. kyk; Kjypa gjpdhd;F tpiuTfis ntspg;gLj;jy; 
5. rhuk; Kjypa VO clw;fl;Lfl;Fk; xj;j epfo;r;rpiaj; juy; 
6. Ik;nghwpfl;F td;ikiaf; nfhLj;jy; 
 
tiffs;-10 
1. gpuhzd; 
   ghz;L Nehapy; %r;Rtpl rpukk; czT nrhpahik Vw;gLk;. 
2. mghdd; 
    ghz;L Nehapy; cztpd; rhuk; NruNtz;ba ,lq;fspy; Nrh;g;gpf;fhJ. 
fopr;ry; kyf;fl;L rpWePh; FiwT cz;lhf;Fk; 
3. tpahdd; 
    ghz;L Nehapy; cly; tPf;fk; fz; cjL ntSj;jy; cz;lhFk;. 
4. cjhdd; 
    ghz;L Nehapy; mjpf ePh;Ntl;if cz;lhFk;. 
5. rkhdd; 
    ghz;L Nehapy; grpapd;ik Vw;gLk;. 
6. ehfd; 
    ,ay;G 
7. $h;kd; 
    ,ay;G 
8. fpUfud;  
      grpapd;ik cz;lhf;Fk; 
9. Njtjj;jd; 
     ghz;L Nehapy;J}f;fkpd;ik cz;lhFk;. 
10. jdQ;nrad; 
     ghz;L Nehapy; ghjpg;gilahJ. 
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ghz;L Neha; tu Kjy; fhuzk; gpj;jf; Fw;wkhFk;. gpj;jk; thoplk; kw;Wk; 
mjd; Fzq;fis gw;wp tphpthf tpsf;fpAs;Nsd;. 
 
gpj;jk; thOkplk; 
     gpq;fiy> gpuhzthA> ePh;g;ig> %yhf;fpdp> ,Ujak;> jiy> nfhg;G+o;> ce;jp> 
,iug;ig> tpah;it> ehtpY}Wfpd;w ePh;> nre;ePh;> rhuk;> fz;> Njhy;. 
 
gpj;jj;jpd; tbtj;jd;ik 
     gpj;jj;jpd; ,aw;if tbtk; mZj;JtkhFk; 
 
,aw;ifg; gz;G 
      jd; ,aw;if epiyapy; epd;W nrhpg;gpj;jy;> ntk;ik> ghh;it> grp> 
ePh;Ntl;if> Rit> xsp> epidg;G> mwpT> td;ik> nkd;ik vd;git cz;lhf;fp 
clw;Fj; Jiz GhpAk;. 
 
nghJFwpFzk; 
 ntg;gk; 
 $h;ik 
 nea;g;G 
 nefpo;r;rp 
    gpj;jk; ve;j nghUSld; NrUfpwNjh mjd; Fzj;ij milAk;. 
 
td;ik milAk; NghJ cz;lhFk; Fzq;fs; 
1. gRik 
2. mf;fpdp 
3. F&uk; 
4. ry&gk; 
5. Gspg;G 
6. fhuk; 
    gpj;jj;jpd; td;ik ,e;j MW Fzq;fis mwpFwpahfj; Njfj;jpd;fz; 
,af;Fkhjyhy; ,jw;Fj; jFe;j ghpfhuk; nra;jy; mtrpak;. 
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vjph;Fzq;fs; 
1. twl;rp 
2. Fsph;r;rp 
3. rhe;jk; 
4. nfl;b 
5. ,dpg;G 
6. frg;G 
     ,e;j MW Fz&gq;fisAila Mfhuk; cl;nfhs;sy; Ntz;Lk;. 
 
gpj;jj;jpd; njhopy;fs; 
1. clypy; ntg;gKz;lhjy; 
2. nre;epwk; my;yJ kQ;rs; epwk; Njhd;wy; 
3. cz;l czTg; nghUl;fs; gf;FtkilAk; NghJk; nrhpf;Fk; rkaj;jpYk; 
ntg;gKz;lhjy; 
4. tpah;j;jy; 
5. kaf;fk; Vw;gly; 
6. nre;ePh; jd; mstpy; kpFjy; mt;thW kpFe;j nre;ePh; ntspg;gLjy; 
7. Njhy; fz; kyk; rpWePh; Kjypad kQ;rs; epwkiljy; 
8. rPw;wk; tzf;fkpd;ik mirtpd;ik epidT ntwp nkypT vhpT 
cz;lhjy; 
9. vr;RitAk; ifg;ghfNtDk; Gspg;ghfNtZk; fhZjy; Mfpait 
moypd; njhopy;fshFk;. 
 
gpj;jk; - Rit 
       ,uz;buz;L G+jr;Nrh;f;ifahy; xt;nthU RitAk; cz;lhfpwJ. 
 jPapd; $W ,Uf;Fk; Ritfs; gpj;jj;ij mjpfhpf;fr; nra;Ak;. mit 
    cg;G - ePh; +  jP 
    Gspg;G - kz; + jP 
    fhh;g;G - tsp + jP 
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gpj;jj;ij rkg;gLj;Jk; Ritfs; 
 Jth;g;G> ,dpg;G> ifg;G 
    “gpj;j kjpfhpg;gpd; NgRk; ghpfhuk; 
     Rj;jj; JtNuhL nrhy;ypdpg;Gr; rj;jhFk; 
     ifg;Gr; RitNa fUJtjd; tPW 
     Va;g;GilA nkd;Wiuj;jh hpq;F” 
                                                 -fz;Zrhkpak;. 
gpj;jj;jpd; tiffs; 
1. mdw;gpj;jk; 
   ghz;L Nehapy; grpapd;ik cz;lhFk; 
2. ,uQ;rf gpj;jk; 
   ghz;L Nehapy;fz; nts;tpop Njhy; ntSj;jpUf;Fk; 
3. rhjf gpj;jk; 
   md;whl gzpfis rhptu nra;a ,ayhky; cly;Nrhh;T cz;lhFk; 
4. MNyhrf gpj;jk; 
    ,ay;G 
5. gpuhrf gpj;jk; 
    ghz;L Nehapy; fz; nts;tpop Njhy; ntSj;jpUf;Fk;. 
 
nre;ePh; cUthf;fk; - Njiuah; nfhs;if 
        Kjy; ehs; cz;l cztpdpd;Wk; gphpTw;w md;d urkhdJ md;iwf;F 
,ur jhJit eidj;J Cwp;j; jq;Fk;. ,uz;lhk; ehs; cz;l md;durk; me;j ur 
jhJtpNyw Kd;G Cwp epd;w urk; ,uj;j jhJtpw; ghAk;. 
,t;thNw 
%d;whk; ehs; - Cz; jhJtpYk; 
Ehd;fhk; ehs; - nfhOg;G jhJtpYk; 
Ie;jhk; ehs; - vd;G jhJtpYk; 
Mehk; ehs; - k[;i[ jhJtpYk; 
Vohk; ehs; - Rf;fpyj; jhJtpYQ; 
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     nrd;W mj;jhJf;fis tpUj;jpailar; nra;J vl;lhk; ehs; clw;Ff; Fd;whj 
td;ikiaf; nfhLf;Fk;. 
 
    ghz;L Nehapy; rhuk; nre;ePh; ghjpf;fg;gLfpwJ. 
 
gpzpawpKiwik 
    gpzpawp Kiwik vd;gJ cliyg; gpzpj;jyha Nehiaj; njhpe;Jnfhs;Sfpw 
xOf;fk; vdg;gLk;. 
 
        ,J nghwpahh;Nwh;jy; Gydhywpjy; tpdhjy; vd;Dk; tpjpfisAk; 
mtw;iwj; Jizahfg;gw;wp xOFk; xOf;fq;fisAk; Fwpf;Fk;. 
 
1. nghhwpahh;Nwh;jy; 
   Njhy;     - if fz; eff;fz; ntSj;jy;. 
    eh       - nkd;ikahd gOg;G epwkhd gsgsg;ghd ehf;F 
    fz;      -  nts; tpop ntSj;jy;. 
    %f;F     - ,ay;G 
    fhJ      -  ,ay;G 
 
2. Gydhywpjy; 
   Rit    -  Ritapd;ik 
    ghh;it  -  kq;fpa ghh;it 
    CW    -  Njhy; twl;rp 
    xyp    -  fhJ ,iur;ry;. 
    kzk;   -  ,ay;G 
     
3. tpdhjy; 
    Nehahsp ngah;> taJ> njhopy;> ,lk;> FLk;g #o;epiy> FLk;g tuyhW> 
Nehapd; fhyk;> Ke;ija tuyhW> fhy khWghLfs;> kUe;J vLj;Jf; 
nfhz;ljw;fhd tuyhW kw;Wk; gof;ftof;fq;fs; Mfpatw;wpid Nehahsp 
my;yJ ngw;Nwhhplk; Nfl;L ngWjy;. 
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ghz;L Nehapy; vz;tifj; Njh;T 
vz;tifj; Njh;Tfs; 
    gpzpia mwpAk; top kUj;Jt E}y; ty;Nyhh;fshy; vz; tifaha; 
tFf;fg;gl;Ls;sJ. 
     ‘ehbg;ghprk; ehepwk; nkhoptpop 
      kyk; %j;jpukpit kUj;JtuhAjk;” 
                                               - Neha; ehly; Neha; Kjy; ehly;. 
vd;gjdhYk; 
 
      ‘nka;f;Fwp epwe;njhdp tpopehtpUkyk; iff;Fwp” 
vd;Dk; Njiuah; thf;fpdhYk; mwpayhk;. 
 
ehb 
    ‘nfhz;blNt faNuhfp fhr Nuhfp 
          Fwpg;ghfr; rpw;wpd;gk; nra;j Ngh;fs; 
     mz;blNt jhpj;jpuh;fs; tpUj;jh; ghyh; 
          md;ghfj; jz;zPhpy; %o;fpNdhh;fs; 
     nfhz;blNt ,th;fsJ cWg;gpd; jhJ 
          $wNt KbahJ vth;f;Ff; fpl;Lk; 
     gz;blNt ,g;ghPl;ir ahh;jhd; fhz;ghh; 
          guhguj;jpd; kfpikapJ ghU ghNu” 
                                                      -Neha; ehly; Neha; Kjy; ehly;  
ghyh;fSf;F ehb eilapd; cz;ik rhpahfg; Gydhfhthk;. vdNt ghz;L 
Nehapdhy; ghjpf;fg;gl;l Foe;ijfspd; ehbeil ,ad;wtiuapy; Ma;thsuhy; 
vLj;Jf; fhl;lg;gl;Ls;sJ. 
 
ghz;L Nehapd; ehb eil 
 gpj;j ehb 
    ‘MNkjhd; mj;jpRuk; ghz;L Nrhif 
        Mohd tplhr;RuKk; gpuNk fe;jhd; 
     NghNkjhd; fhkhiy gpj;j ntl;il 
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         nghy;yhj ghz;LlNd rpte;j ePuhk; 
     NjfNkjhd; rptg;ghA kQ;r shAQ; 
         rpWrpWj;J ,Uz;LtUq; foptp Oe;J 
     ehNkjhd; nrhd;NdhNk gpj;jf; $W 
         etpd;wpl;lhh; thrKdp etpd;wpl; lhNu” 
                                                       -mfj;jpah;. 
 Ia ehb 
 Ia thjk; 
 Ia gpj;jk; 
 
];ghprk; 
     Njhy; twl;rp> nrhwnrhwg;G fhZk; 
eh 
     ghz;L Nehapy; eh ntSg;G> Ritapd;ik cz;lhFk;. 
epwk; 
     cly;> fz; nts;tpop> eff;fz; ntSg;G cz;lhf;Fk;. 
nkhop 
       ,ay;G 
tpop 
    ghz;L Nehapy; fz; nts;tpop ntSj;jpUf;Fk; 
kyk; 
     kyf;fl;L fopr;ry; Vw;gLk;. 
%j;jpuk; 
ePh;f;Fwp- ghz;L Nehapy; 
   rpWePh; mstpy; FiwAk;. 
nea;f;Fwp 
    ‘tpiuTld; fjph;Nghy; ePz;L Ntw;Wikf; Fzq;fs; fz;lhy; 
     FUjpjhd; nfl;L ehrk; Fd;wpa Fzknjd;Nd” 
                                                            -Njiuah; 
   ghz;L Nehapy; fjph; Nghy; guTk;. 
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gUtfhyq;fs; 
      fhh; fhyk; kw;Wk; $jph; fhyk;.  ,t;tU fhyq;fspy; gpj;jk; jd;dpiy 
tsh;r;rp kw;Wk; Ntw;Wepiy tsh;r;rp milAk;. 
 
epyk; 
      FwpQ;rp nea;jy; kw;Wk; ghiy epyj;jpy; thOk; kf;fSf;F ghz;L Neha; 
tUtjw;fhd tha;g;Gfs; cs;sd. 
 
ghz;L jPUk; jPuhf; Fwp 
                ‘mrhj;jpakhk; rpNyj;JkKk; njhe;jk; nuj;jk; 
          mfYNk thjgpj;jk; rhj;jpakhFk;” 
                                           -Foe;ij Neha;fs; rpjk;gujhDgps;is 
 
     Foe;ijfSf;F cz;lhFk; Ie;J tif ghz;L Neha;fspy; thj ghz;L> 
gpj;jg; ghz;L ,uz;Lk; rhj;jpak; 
 
     rpNyj;Jkg; ghz;L> njhe;j ghz;L> uj;j ghz;L Mfpa %d;Wk; mrhj;jpak;. 
 
mrhj;jpa ghz;L 
      ghz;L Nuhfpf;F tPf;fk>; Nrhk;gy; > jhfk;> mNuhrfk; > the;jp > tpf;fy;> 
,Uky;> Ngjp vd;Dk; ,f;Fzq;fs; cz;lhfp ve;j nghUisg; ghh;j;jhYk; kQ;rs; 
epwKz;lhdhy; mrhj;jpak; 
                                                        -mfj;jpah; itj;jpa gps;isj;jkpo; 
 
fz;Zrhkpak; 
          ‘ghz;L gpuNkfk; gd;thj #iy Fd;kk;  
           Ntz;lh raQ;rd;dp ntz; Nrhig - ePz;l 
           mjpePNu fhkhiy ahdgpzp jk;K 
           sjp rhukh fhjwp” 
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           ‘nrhy;Y gpj;jj;jpw; Nrhig Nrhigjdpy; thAnjhe;jk; 
            ty;ytjpw; ghz;Ltd; ghz;by; -ey;y 
            tapw;Wf; fLg;G tsh;fLg;Gw; rPjk; 
            gapypw; nfLjp nadg;gd; 
 
            ntg;Gg; gpzpajdpy; ntk;Nkfj;jhy; tUe;jpd; 
            jg;G kpif ePNu jhdpwq;fpd; - nrg;Gk; 
            fpuhzpapw; ghz;by; fpsh; ePh;RUq;fpw; 
            gpuhzd; gphpAnkdg; NgR” 
  
ruNge;jpuh; itj;jpa Kiwfs; 
        tPf;fj;jpy; kQ;fs; epwk; fhzg;gl;lhy; Fzk; Vw;glhJ. kyrpf;fNyh 
my;yJ gr;ir epwkhd mjprhuNkh Vw;gl;lhy; mrhj;jpak;. gytPdk;> the;jp> 
%h;r;ir> mjpf ehshd ghz;L Nuhfk; rpfpr;irf;F trg;glhJ GjpjhdhYk; cly; 
ehtwl;rp> ,uj;j Fiwtpdhy; cly; ntSg;G KjypaitfSld; $ba NuhfpAk; 
FzkiltJ rpukk;. 
 
         gw;fs;> efk;> fz; ,itfs; mjpfk; ntSj;jhYk; vy;yhtw;iwAk; 
ntz;zpwkhf ghh;j;jhYk; me;j Nuhfk; mrhj;jpakhFk;. mrhj;jpa Nuhfj;ij 
Kw;wpYk; Fzg;gLj;j Kbahtpl;lhYk; rpwpJ FwpFzq;fis Fiwj;J 
MAisAk; rpy fhyk; ePbf;fr; nra;ayhk;. 
 
        iffs; fhy;fs; jiy Kjyhd ,lq;fspy; tPf;fk; Vw;gl;L ,isj;J 
iffhy;fSk; ,isj;J tapW ngUj;Jk; cs;s ghz;L NuhfpiaAk; Mz;Fwp> 
njhilapLf;F Mfpa ,lq;fspy; tPf;fk;> mbf;fb kaf;fk;> mjprhuk;> Ruk; 
Mfpad fz;L tUk; NuhfpiaAk; Fzg;gLj;JtJ mrhj;jpakhFk;. 
 
khjt epjhdk; 
     ghz;Ltpd; mrhj;jpa ,yl;rzq;fs; 
1. ePbj;J njhlh;tJk; kpf;f Kjph;e;J NghdJkhd ghz;L rpfpirf;F 
trg;glhJ 
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2. mtaq;fs; tPq;fpg; Ngha; vy;yhg; nghUSk; kQ;rshf Njhd;wpdhy; 
jPuhJ. 
3. ,Wfpa nrhw;g kyj;Jld; kQ;rs; ePuhfTk; fgj;Jld; $bajhfTk; 
mjprhuk; cz;lhdhy; mrhj;jpak;. 
4. mjpf jPj;jd;ik mile;J mtaq;fs; ntz;ikahfp the;jp %h;r;ir 
ehtwl;rp cz;lhdhy; mrhj;jpak;. 
5. ,uj;jk; nfl;L cly; Kw;Wk; ntSj;jhy; jPuhJ. 
6. Njfj;jpd; if> fhy;> jiy tPf;fk; cly;tw;wp ,isj;Jg; Nghdhy; Fjk;> 
Mz;Fwp >gP[k; tPf;fk; ,Ue;jhy; jPuhJ. 
7. kpf;f ,isg;G kaf;f epiy fhzg;gl;lhy; jPuhJ. 
8. mjprhuk; Ruk; nfhz;l ghz;L jPuhJ. 
 
kUj;Jtg; ghpfhuk; 
    gpzpf;fg;gl;l tsp> moy;> Iak; vd;Dk; Kf;Fw;wj;ijj; jd;dpiyg; 
gLj;Jjy; kUj;Jtk; vd toq;fg;gLk;. gpzpf;fg;gl;l Kf;Fw;wq;fs; Ik;Gyd;fs;> 
VO clw;jhJf;fs; Mfpaitfis jd;dpiyg;gLj;Jk; jd;ikAilait 
kUe;jhFk;. 
 
          kUe;J mfkUe;njd;Wk; GwkUe;njd;Wk; ,Ugphpthff; nfhs;spDk; 
Kf;fpakhf jhtug;nghUs;> jhJg;nghUs;> rq;fkg; nghUs; vd %d;W tifahf 
tFj;jdh;. ,jid Njud; $wpa gpufhuk; 
 
          ‘fw;gq;f shjp foW kUe;J Kiw 
           tpw;gdq; fshf tpsq;Ftjw;F  - Kw;gq;F 
           %ypf; fUg;nghUs; %yg;nghUs; tiffs; 
           Ntypf;F Neuh FNk”. 
 
        rpj;j kUj;Jt Kiwg;gb Neha;f;F kl;Lk; kUj;Jtkpd;wp mjid tuhJ 
jLf;fTk; fhafw;gkhfTk; kUe;Jfs; gad;gLk; 
       ‘cw;wh dsTk; gpzpasTq; fhyKq; 
        fw;whd; fUjpr; nray;”. 
  -jpUf;Fws; 
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Nehapdd; mile;j Fw;w NtWghLfspd; kpFjy; Fiwjy; msitAk; 
mjdhy; NehAw;whd; ngw;w Nehapd; msitAk; mwpe;jgpd; Nehapd; fhy msit 
mwpe;J rpe;jpj;J jFe;j kUj;Jtk; GhptJ mtrpak;. 
 
kUj;Jt topKiw 
         Nflile;j Kf;Fw;wk; thAf;fs;> ,uj;jj;jhJ ,jid rkg;gLj;Jk; 
kUe;Jfshf ,Uf;f Ntz;Lk;. ehk; nfhLf;Fk; kUe;JfshdJ 
,uQ;rfg;gpj;jj;ij rkg;gLj;jp ,uj;jj;jhJit jd; ,ay;ghd Ntiyfs; 
nra;tjhf khw;w Ntz;Lk;. 
 
       “tpNurdj;jhy; thje; jhOk; 
        tkdj;jhy; gpj;je; jhOk; 
        erpamQ;rdj;jhy; fge; jhOk;”. 
 
       mjpfhpj;j gpj;jj;ij jd;dpiyg;gLj;j the;jp kUj;Jtk; nra;jy; Ntz;Lk;. 
ghz;L Nehapy; Nehahsp Nrhh;thfTk;> jsh;TlDk; ,Ug;gjhy; the;jp Kiw 
kUj;JtkhdJ nfhLg;gjpy;iy. 
 
 ,uj;jj;jhJit mjpfhpf;f mak; rhh;e;j kUe;Jfis 
toq;fNtz;Lk;. 
 Neha;f;fhd fhuzq;fisj; jtph;f;f Ntz;Lk; 
 grpj;jPia mjpfhpf;fr; nra;Ak; kUe;Jfis toq;f Ntz;Lk; 
 gj;jpak; vspjhf ,Uf;f Ntz;Lk; 
 mjpf rj;Js;s czit cl;nfhs;s nra;a Ntz;Lk;. 
,jw;fhf Ma;Tfl;Liu Mrphpah; “ghz;L Neha;f;fhd fyg;Gj; 
J}s;” vDk; kUe;ij ghz;L Neha;f;fhf vLj;Js;shh;. 
 
czT 
    Neha; njhlf;fj;jpy; grpiaj;J}z;lf;$baJk;> clypd; FUjpia 
ngUf;ff;$baJkhd czTg; nghUl;fisg; nghpJk; ifahsy; Ntz;Lk;. 
czTk; vspjpy; nrhpf;ff;$bajhfNt ,Uj;jy; Ntz;Lk;. 
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fPiu tiffs; 
       fhprhiy> nghd;dhq;fhzp> mWfPiu> rpWfPiu> kzj;jf;fhsp> jhsPf;fPiu 
fha;fwpfs; 
      fj;jhp gpQ;R> KUq;ifg; gpQ;R> thiof;fr;ry;> mtiug;gpQ;R. 
goq;fs; 
      nfhbKe;jphpif> rhj;Jf;Fb> Mg;gps;> mj;jpg;gok;> khJisg;gok;> ney;yp. 
fwptiffs; 
    nts;shl;Lf;fwp> fhil> nfsjhhp 
 
ghz;L Neha;f;F toq;Fk; %ypifg; nghUl;fs; 
            ‘nrg;GfpNwd; ghz;L fhkhiy Nrhif 
             jPh;f;fpd;w ruf;F tha;tpsq; fe;jhk; 
             xg;gpy;yh $tpis Nth; ej;ijr; #hp 
             Crpky;yp kUl;fpoq;F ey;yNtis 
             xg;gpy;yhky; %ypfhpg; ghd; r%yk; 
             cUf;F kz;^ Nu kak; Riuf; nfhOe;J 
             nrg;ghk;gpj; jisg;gw;gk; Gspak;gl;il 
             rpWgPis jha;f nfhl;lhd; rpWfPiu Nth; 
             NtnuhL ntz;fhuk; G+idf; fhyp 
             tpj;J ,sePh; Kj;J fPo;f;fha; ney;yp 
             NtNuhL G+te;jpg; gok; muj;ij 
             nts;isf; fhf;fz Nth; fhl;lh kzf;F 
             NtNuhL G+kp rh;f;fiuf; fpoq;F 
             nts;shl;bd; ePh; ghy; rhuiz Nth;fs;sp 
             NtNuhL [ykQ;rhpr; nre;J}uk; 
             kpsF jf;fhspapiy ney;ypapd; Nth; 
             ney;yp Nth; jpidf; fQ;rp %Rky;yp 
             ePh; Ks;sp r%yk; G+turk; gl;il 
             nfhy;yd; Nfhit Aila r%yk; tl;lf; 
             fpYfpYg;ig thioePh; thioAl;b 
             tpy;t ,iy ghjphpNth; Fsj;Jg; ghiy 
33 
 
             NtNuhL NfhkpaKk; m];tfe;jp 
             fy;ahz fug;ghd; jf;NfhyKk; gpuk;kp 
             fhuhd; jphpfLF ghiy FwpQ;rh 
             FUQ;rh ehfzk; GspapDiyap NdhL     
             $wpa ,t;itk;gj; njl;L ruf;Fk; 
            ngUe; njhy;iyahk; ghz;L Nrhif tPf;fk; 
            gpj;jj; jhnyLj;j njhU Nehia nay;yhk; 
            ngUe; njhiyapNyhl;L tpf;Fk; 
            gjhh;j;j Fz tpsf;fk; 
                                      -itj;jpa rh];jpuk; 
   
nghUs; :  
tha;tpsqk;> ej;ijr;#hp> ey;yNtis> fhpg;ghd; r%yk;> Riuf;nfhOe;J> 
Riuf; nfhOe;J> rpWgPis> rpWfPiuNth;> G+idf;fhyp tpij> ,sePh;> fPohney;yp> 
muj;ij> nts;isf; fhf;fd Nth;> fhl;lhkzf;F Nth;> G+kp rh;f;fiuf; fpoq;F> 
rhuiz Nth;> ney;yp> jpidf; fQ;rp> ePh;Ks;sp r%yk;> G+turk; gl;il> 
nfhy;yd;Nfhit> tl;lf; fpYfpYg;ig> thioePh;> tpy;t,iy> ghjphpNth;> 
m];tfe;jp> jf;Nfhyk;> gpuk;kp> jphpfLF. 
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MODERN ASPECT 
INTRODUCTION 
              Blood is a connective tissue in fluid form. It is considered as the „fluid of life‟ 
because it carries oxygen from lungs to all parts of the body and carbon dioxide from all 
parts of the body to lungs. It is known as „fluid of growth‟ because it carries nutritive 
substances from digestive system and hormones from endocrine gland to all the tissues. 
The blood is also called the „fluid of health‟ because it protects the body against the 
diseases and gets rid of the waste products and unwanted substances by transporting them 
to the excretory organs like kidneys. 
 
PROPERTIES OF BLOOD 
1. COLOUR 
        Blood is red in color. Arterial blood is scarlet red because it contains more 
oxygen and venous blood is purple red because of more carbon dioxide. 
 
2. VOLUME 
        Average volume of blood in a normal adult is 5 L. In a newborn baby, the 
volume is 450 ml. It increases during growth and reaches 5 L at the time of 
puberty. In females, it is slightly less and is about 4.5 L.  
 
3. REACTION AND PH 
         Blood is slightly alkaline and its pH in normal condition is 7.4. 
 
4. SPECIFIC GRAVITY 
          Specific gravity of total blood  : 1.052 to 1.061 
          Specific gravity of blood cells : 1.092 to 1.101 
          Specific gravity of plasma        : 1.022 to 1.026 
 
5. VISCOSITY 
         Blood is five times more viscous than water. It is mainly due to red blood 
cells and plasma plasma. 
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COMPOSITION OF BLOOD 
Blood is classified as a connective tissue and consists of two main components: 
1. Plasma, which is a clear extracellular fluid 
2. Formed elements, which are made up of the blood cells and platelets 
The formed elements are so named because they are enclosed in a plasma membrane and 
have a definite structure and shape. All formed elements are cells except for the platelets, 
which are tiny fragments of bone marrow cells. 
 
Formed elements are: 
 Erythrocytes, also known as red blood cells (RBCs) 
 Leukocytes, also known as white blood cells (WBCs) 
Platelets 
 
Leukocytes are further classified into two subcategories called granulocytes 
which consist of neutrophils, eosinophils and basophils; and agranulocytes which consist 
of lymphocytes and monocytes. 
 
The formed elements can be separated from plasma by centrifuge, where a blood 
sample is spun for a few minutes in a tube to separate its components according to their 
densities. RBCs are denser than plasma, and so become packed into the bottom of the 
tube to make up 45% of total volume. This volume is known as the haematocrit. WBCs 
and platelets form a narrow cream-coloured coat known as the buffy coat immediately 
above the RBCs. Finally, the plasma makes up the top of the tube, which is a pale yellow 
colour and contains just under 55% of the total volume. 
 
Blood plasma 
Blood plasma is a mixture of proteins, enzymes, nutrients, wastes, hormones and 
gases. The specific composition and function of its components are as follows: 
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Proteins 
These are the most abundant substance in plasma by weight and play a part in a 
variety of roles including clotting, defence and transport. Collectively, they serve several 
functions: 
 
 They are an important reserve supply of amino acids for cell nutrition. Cells called 
macrophages in the liver, gut, spleen, lungs and lymphatic tissue can break down 
plasma proteins so as to release their amino acids. These amino acids are used by other 
cells to synthesise new products. 
 
 Plasma proteins also serve as carriers for other molecules. Many types of small 
molecules bind to specific plasma proteins and are transported from the organs that 
absorb these proteins to other tissues for utilisation. The proteins also help to keep the 
blood slightly basic at a stable pH. They do this by functioning as weak bases 
themselves to bind excess H+ ions. By doing so, they remove excess H+ from the 
blood which keeps it slightly basic. 
 
 The plasma proteins interact in specific ways to cause the blood to coagulate, which is 
part of the body‟s response to injury to the blood vessels (also known as vascular 
injury), and helps protect against the loss of blood and invasion by foreign 
microorganisms and viruses. 
 
 Plasma proteins govern the distribution of water between the blood and tissue fluid by 
producing what is known as a colloid osmotic pressure. 
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FUNCTION OF BLOOD 
1. NUTRITIVE FUNCTION 
          Nutritive substances like glucose, amino acid, lipids and vitamins derived 
from digested food are absorbed from gastrointestinal tract and carried by blood to 
different parts of the body for growth and production of energy. 
 
2. RESPIRATORY FUNCTION 
             Transport of respiratory gases is done by blood. It carries oxygen from 
alveoli of lungs to different tissues and carbon dioxide from tissues to alveoli. 
 
3. EXCRETORY FUNCTION 
               Waste products formed in the tissues during various metallic activities are 
removed by blood and carried to the excretory organs like kidney, skin, liver, etc. 
for excretion. 
 
4. TRANSPORT OF HORMONES AND ENZYMES 
              Hormones which are secreted by ductless glands are released directly into 
the blood. The blood transports these hormones to their target organs/ tissues. Blood 
also transports enzyme. 
 
5. REGULATION OF WATER BALANCE 
    Water content of the blood is freely interchangeable with interstitial fluid. 
This helps in the regulation of water content of the body. 
 
6. REGULATION OF ACID BASE BALANCE 
           Plasma proteins and hemoglobin act as buffers and help in the regulation 
of acid -base balance.   
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7. REGULATION OF BODY TEMPERATURE 
          Because of the high specific heat of blood, it is responsible for 
maintaining the thermoregulatory mechanism in the body, i.e. the balance between 
heat loss and heat gain in the body. 
 
8. STORAGE FUNCTION 
              Water and some important substances like proteins, glucose, sodium and 
potassium are constantly required by the tissues. Blood serves as a readymade 
source for these substances. And, these substances are taken from blood during the 
condition like starvation, fluid loss, electrolyte loss, etc. 
 
9. DEFENSIVE MECHANISM 
              Blood plays an important role in the defense of the body. The white blood 
cells are responsible for this function. Neutrophils and monocytes engulf the 
bacteria by phagocytosis. Lymphocytes are involved in development of immunity. 
Eosinophils are responsible for detoxification, disintegration and removal of foreign 
proteins. 
 
RED BLOOD CELLS 
Red blood cells are the non-nucleated formed elements in the blood. Red blood 
cells are known as erethrocytes. Red color of the red blood cell is due to the presence of 
the coloring pigment called hemoglobin. RBCs are more in number compared to the other 
two blood cells, namely white blood cells and platelets. 
 
MORPHOLOGY OF RED BLOOD CELLS 
 NORMAL SHAPE 
              Normally, the RBCs are disc shaped and biconcave (dumbbell shaped). 
Central portion is thinner and periphery is thicker. The biconcave contour of 
RBCs has some mechanical and functional advantages. 
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 NORMAL SIZE 
            Diameter         : 7.2µ (6.9 to 7.4µ) 
              Thickness        : At the periphery it is thicker with 2.2µ and at the center it is 
thinner with 1µ. This difference in thickness is because of the biconcave shape. 
              Surface area     : 120 sq µ 
              Volume            : 85 to 90 cu µ 
 NORMAL STRUCTURE 
RBC has a special type of cytoskeleton, which is made up of actin and spectrin. 
 
PRODUCTION OF ERYTHROCYTES 
Areas of the body that produce erythrocyte cells are 
1. In the early few weeks of embryonic life – yolk sac 
2. During the middle trimister of gestation – Liver, Spleen, Thymus and 
Lymphnodes. 
3. Later part of gestation and after birth  - Red bone marrow 
4. Up to the age of five – Red marrow of all the bones. 
5. After the age of 5 and adult – Red marrow of proximal end of long bones and 
flat bones such as ribs, vertebrae, pelvis, sternum and iliac bone. 
 
Sometimes under conditions of exchanged stimuli, reticulo endothelial system 
also takes up the embryonic function and yellow marrow shall be transformed into the red 
marrow. Even in these bones, the marrow becomes less productive as age increases. 
 
GENESIS OF RED BLOOD CORPUSCLES 
In the bone marrow there are cells called Pluripotential  Haemopoietic  Stem  
Cells (PHSC) from which all the cells in the circulating blood are derived. The large 
portion of reproduced stem cells differentiates to form the other cells. The early offspring 
still cannot be recognized as the different types of blood cells, even though they have 
already become committed to a particular line of cells and are called committed stem 
cells. 
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The different committed stem cells will produce colonies of specific types of 
blood cells. There, a committed stem cell that produces colony – forming unit blast  
(CFU-B) and then erethrocytes  produced from these are called colony forming unit – 
erythrocytes( CFU-E) 
 
 
STAGE OF DIFFERENTIATION OF RED BLOOD CORPUSCLES 
Colony forming unit erythrocyte (CFU-E)[primordial stem multipotential] 
 
 
Proerythroblast [First cell that belonging the RBC series – unipotential] 
 
 
Basophil erythroblast[Begins synthesis of haemoglobin] 
 
 
Poly chromatophil erythroblast[contains basophilic cytoplasm and haemoglobin] 
 
 
Normoblast[with small nucleus and more haemoglobin- orthrochromic erythroblast] 
 
 
Reticulocytes[small amount of basophilic reticulum is present] 
 
 
Erythrocytes[Matured red blood corpuscles.] 
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STAGE OF MATURATION OF THE RBC  
Stage 1- Pro erythroblast (Megaloblast) 
This early cell is large (15-20) µ and contains no haemoglobin. The cytoplasm is 
basophilic. The nucleus is about 12µ and occupies about three quarters of the cell volume 
and the chromatin forms a fine stippled reticulam 
 
Stage 2- Early Normoblast (Early erythroblast) 
This cell is smaller than pro erythroblast and shows active mitosis. The nucleoli 
disappeared and cytoplasm is basophilic. 
 
Stage 3- Intermediate Normoblast (Late erythroblast) 
This cell is smaller (10- 15)µ and shows active mitosis. Haemoglobin beings to 
appear and its eosinophilic staining give cytoplasm a polychromatic appearance. 
 
Stage4- Late Normoblast (Normoblast) Substances necessary for the 
formation of erythrocytes corpuscles: 
Mitosis has now ceased and the diameter of cell is 7- 10µ. The nucleus is smaller 
and the condensed chromatin assumes a “cart wheel” appearance and finally becomes 
deeply stained in a uniform manner. This appearance is called pyknosis and is a stage in 
the degeneration of the nucleus, which breaks up and finally disappears owing to the 
extrusion or lysis and a young RBC (reticulocyte) is formed. The maximum level of 
haemoglobin is attained and the cytoplasm gives eosinophilic reaction. 
 
Maturation of erythroblasts thus involves a decrease in the size of the cell, 
increased condensation and finally pyknosis of the nucleus. There is accumulation of 
haemoglobin and a change in the staining reaction of the cytoplasm from the basophilic 
to eosinophilic viz polychromatophil. 
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Substances necessary for the formation of erythrocytes corpuscles: 
Protein, Iron, Copper, Manganese, Vitamins (B12, C and Folic acid), Internal 
secretions (Thyroxine), Hormones (erythropoietin, androgens and thyroxine). 
 
FUNCTIONS OF RED BLOOD CELLS 
1. Transport of oxygen from the lungs to the Tissues 
        Hemoglobin in RBC combines with oxygen to form oxyhemoglobin. About 97% 
of oxygen is transported in blood in the form of oxyhemoglobin. 
 
2. Transport of Carbon Dioxide from the tissues to the lungs 
           Hemoglobin combines with carbon dioxide and form carbhemoglobin. About 
30% of carbon dioxide is transported in this form. 
 
             RBCs contain a large amount of the carbonic anhydrase. This enzyme is 
necessary for the formation of bicarbonate from water and carbon dioxide. Thus, it 
helps to transport carbon dioxide in the form of bicarbonate from tissues to lungs. 
About 63% of carbon dioxide is transported in this form. 
 
3. Buffering action in Blood 
           Hemoglobin functions as a good buffer. By this action, it regulates the 
hydrogen ion concentration and thereby plays a role in the maintenance of acid- 
base balance 
 
4. In blood group Determination 
              RBCs carry the blood group antigens like A antigen, B antigen and Rh 
factor. This helps in determination of blood group and enables to prevent reactions 
due to incompatible blood transfusion. 
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Life span and fate of red blood cells 
Average life span of red blood cell is about 120 days. Daily 10% of red blood 
cells, which are senile, get destroyed in normal young healthy adults. This causes release 
about 0.6% of haemoglobin into the plasma. From this 0.9 to 1.5mg% bilirubin is formed. 
Normal values of erythrocytes 
     Infants      - 4to 4.5 million/cu.mm 
   2-6 years    - 4.5 million/cu.mm 
    6-14 years – 4.5 to 4.8 million/cu.mm 
 
HEMOGLOBIN 
Hemoglobin is the iron containing coloring matter of red blood cell. It is a 
chromoprotein forming 95% of dry weight of RBC and 30% to 34% of wet weight. 
Function of hemoglobin is to carry the respiratory gases, oxygen and carbon dioxide. It 
acts as a buffer. Molecular weight of hemoglobin is 68,000. 
 
NORMAL HEMOGLOBIN CONTENT 
                Average hemoglobin content in blood is 14 to 16 g/dL. However, the value 
varies depending upon the age and sex of the individual. 
 
AGE 
 At birth Hb level  : 25g/Dl 
 After 3rd month : 20g/Dl 
 After 1 year  : 17 g/Dl 
 From puberty onwards  : 14 to 16 g/Dl 
At the time of birth, hemoglobin content is very high because of increased number 
of RBCs 
 
SEX 
 In adult males : 15g/dL 
In adult females : 14.5 g/dL 
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FUNCTIONS OF HEMOGLOBIN 
  Transport of respiratory gases 
1. Oxygen from the lungs to tissues 
2. Carbon dioxide from tissues to lungs 
  Buffer action 
                  Hemoglobin acts as a buffer and plays an important role in acid- base balance. 
 
STRUCTURE OF HEMOGLOBIN 
                   Hemoglobin is a conjugated protein. It consists of a protein combined with 
an iron – containing pigment. The protein part is globin and the iron- containing pigment 
is heme.  
TYPES OF NORMAL HEMOGLOBIN 
         Hemoglobin is of two types: 
1. Adult hemoglobin - HbA 
2. Fetal hemoglobin - HbF 
 
SYNTHESIS OF HEMOGLOBIN 
           Synthesis of hemoglobin actually starts in proerythroblastic stage. However, 
hemoglobin appears in the intermediate normoblastic stage only. Production of 
hemoglobin is continued until the stage of reticulocyte. 
 
            Heme protein of hemoglobin is synthesized in mitochondria. And the protein part, 
globin is synthesized in ribosomes. 
 
SYNTHESIS OF HEME 
Heme is synthesized from succinyl-Co A and the glycine. The sequence of events 
in synthesis of hemoglobin: 
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1. First step in heme systhesis takes place in the mitochondrian. Two molecules of 
succinyl-Co A combines with two molecules of glycine and condense to form α 
aminolevulinic acid (ALA) by ALA synthase. 
2. ALA is transported to the cytoplasm. Two molecules of ALA combine to form 
porphobilinogenin the presence of ALA dehydratase. 
3. Porphobilinogen converted into urophobilinogen - I by urophobilinogen - I 
synthase 
4. uroporphobilinogen - I is converted into uroporphobilinogen - III 
byporphobilinogen - III cosynthase. 
5. From uroporphobilinogen - III, a ring structure called coporphobilinogen - III is 
formed by uroporphobilinogen decarboxylase. 
6. Coprophobilinogen - III is transported back to the mitochondrion, where it is 
oxidized to form protoporphyrinogen - IX by coproporphyrinogen oxidase. 
7. Protoporphyrinogen - IX is converted into protoporphyrin - IX by 
protoporphyrinogen oxidase. 
8. Protoporphyrin - IX combines with iron to form heme in the presence of 
ferrochelatase. 
 
FORMATION OF GLOBIN 
Polypeptide chains of globin are produced in the ribosomes. There are four types 
of polypeptide chains namely, alpha, beta, gamma and delta chains. Each of these chains 
differs from others by the amino acid sequence. Each globin molecule is formed by the 
combination of 2 pairs of chains and each chain is made of 141 to 146 amino acids. Adult 
hemoglobin contains two alpha chains and two beta chains. Fetal hemoglobin contains 
two alpha chains and two gamma chains. 
 
CONFIGURATION 
Each polypeptide chain combines with one heme molecule. Thus, after the 
complete configuration, each hemoglobin molecule contains 4 polypeptide chains and 4 
heme molecules. 
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SUBSTANCES NECESSARY FOR HEMOGLOBIN SYNTHESIS 
Various materials are essential for the formation of hemoglobin in the RBC. 
 
DESTRUCTION OF HEMOGLOBIN 
After the lifespan of 120 days, the RBC is destroyed in the reticuloendothelial 
system, particularly in spleen and the hemoglobin is released into plasma. Soon, the 
hemoglobin is degraded in the reticuloendothelial cells and split into globin and heme. 
 
Globin is utilized for the resynthesis of hemoglobin. Heme is degraded into iron 
and porphyrin. Iron is stored in the body as ferritin and hemosiderin, which are reutilized 
into a green pigment called biliverdin. In human being, most of the biliverdin is 
converted into a yellow pigment called bilirubin. Bilirubin and biliverdin are together 
called bile pigments. 
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ANEMIA 
DEFINITION 
  Anaemia is a condition in which the number of red blood cells or their oxygen-
carrying capacity is insufficient to meet physiologic needs, which vary by age, sex, 
altitude, smoking, and pregnancy status. 
 
Iron deficiency is thought to be the most common cause of anaemia globally, 
although other conditions, such as folate, vitamin B12 and vitamin A deficiencies, chronic 
inflammation, parasitic infections, and inherited disorders can all cause anaemia. 
 
Anemia is the blood disorder, characterized by the reduction in : 
1. Red blood cell count (RBC) 
2. Hemoglobin content 
3. Packed cell volume(PCV) 
 
WHO Criteria for diagnosis of Anemia 
  Children 6 months to 6 year : less than 11 
  Children 6 years to 14 year : less than 12 
- IAP Text Book of Paediatrics 
Grading of Anemia 
WHO grades anemia according to hemoglobin level as follows, 
             Hb between 10 gm and cut off point for age : Mild 
             Hb between 7 to 10 gm : Moderate 
             Hb under 7 gm : Severe 
 
Etiology of Anemia 
            Causes vary with age and anemia may be multifactorial 
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a. New born 
History should include that for maternal infections, collagen vascular diseases, 
prematurity, blood loss, jaundice(hemolysis due to ABO or Rh incompatibility, G6PD 
deficiency, sepsis) and presents of hemangiomas or cephalhematoma. 
 
b. Young infants ( 3 months to 18 months) 
In infants may have physiological anemia at 2- 3 months of age. Delayed or 
inadequate weaning with predominantly milk- based diet results in poor iron intake, 
leading to nutritional iron deficiency, usually occurring at 6 months to 2 yrs of age; other 
causes include chronic diarrhea or cow milk allergy. Megaloblastic anemia may be 
nutritional, due to use of goat milk in infants and a vegetarian diet in older children. 
 
c. Older babies and children 
1. Common causes 
a. Malnutrition and iron deficiency 
b. Infections 
c. Nephritis, Nephrosis 
d. Ankylostomiasis 
 
2. Less common causes 
a. Leukemia 
b. Inherited defects pf RBC, haemoglobinopathies or congenital spherocytosis 
c. Bleeding  disorders like haemophilias, thrombocytopenic purpura and 
petechial bleeding 
d. Rare causes – aplastic anemia and pernicious anemia 
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ETIO- PATHOGENESIS 
1. Anemia due to defects in haemoglobin synthesis 
When there is deficiency of Iron, Vitamin B12, Vitamin C, Folic acid, Pyridoxine, 
Thyroxine, Proteins and Copper, there is decreased haemoglobin synthesis 
 
2. Anemia due to immaturation of red blood cells 
In megaloblastic anemia large nucleated red blood cells are seen in the red 
marrow of the bones. This immaturation is due to non- availability of Vitamin B 12, 
Folic acid. 
 
3. Anemia due to  red blood cell defects 
The life span of matured red blood cells is about 120 days. Sometimes they may 
die within their usual lifetime. This leads to anemia. 
 
PATHOPHYSIOLOGY OF ANEMIA 
Subnormal level of hemoglobincauses lowered oxygen carrying capacity of the 
blood which leads to hypoxia in organs. 
 Increased release of oxygen from hemoglobin 
 Increased blood flow to tissues 
 Maintenance of the blood volume 
 Redistribution of blood flow to maintain the cerebral blood supply 
 
CLASSIFICATION OF ANEMIA 
Anemia is classified by two methods: 
1. Morphological classification 
2. Etiological classification 
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MORPHOLOGICAL CLASSIFICATION 
Morphological classification depends upon the size and color of RBC. Size is 
determined by mean corpuscular volume (MCV). Color is determined by mean 
corpuscular hemoglobin concentration (MCHC). By this method anemia is classified into 
four types. 
 
1. Normocytic Normochromic Anemia 
2. Macrocytic Normochromic Anemia 
3. Macrocytic Hypochromic Anemia 
4. Microcytic Hypochromic anemia  
 
1. Normocytic Normochromic Anemia 
Size and color of RBCs re normal. But the number of RBC is less.  
Post-hemorrhage - early stage  
- Hemolytic anemia  
- IDA - early stage  
- Systemic diseases like endocrinal, renal and hepatic diseases  
- Bone marrow disorders like hypoplastic anemia, myeloinfiltration, dyserythropoiesis, 
myelodysplasia and masked megaloblastosis.   
                      
2. Macrocytic Normochromic Anemia 
RBCs are larger in size with normal color, RBC count is less. Folate and Vitamin 
B12 deficiency, hypothyroidism. 
 
3. Macrocytic Hypochromic Anemia 
RBCs are larger in size. MCHC is less, so the cells are pale Combined deficiency 
of Iron and folate or Vitamin B12 
 
4. Microcytic Hypochromic Anemia 
RBCs are smaller in size with less color. 
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Iron deficiency anemia 
Haemoglobinopathies 
Haemolytic anemia 
 
ETIOLOGICAL CLASSIFICATION 
On the basis of etiology anemia is divided into five types 
1. Hemorrhagic anemia 
2. Hemolytic anemia 
3. Nutrition deficiency anemia 
4. Aplastic anemia 
5. Anemia of chronic diseases 
 
CLINICAL FEATURES OF ANEMIA 
 The hemoglobin level at which symptoms of anemia appear, depends on 
the rate of development of the anemia. Symptoms occur at higher 
hemoglobin levels if anemia develops rapidly, as with hemorrhage.  
 
 The most common and earliest symptoms include lassitude, and easily 
fatigability. Alternatively, children may have anorexia, irritability and 
poor school performance. 
 
 Dyspnea on exertion, tachycardia and palpitations indicate severe anemia. 
 
 Other symptoms include dizziness, headache, tinnitus, lack of 
concentration and drowsiness and with severe anemia, clouding of 
consciousness. 
 
 The most prominent and characteristic sign is pallor, detected most 
reliably in nail beds, oral mucous membranes and conjunctivae.  
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 Observing  palmar creases and skin is insufficient as the skin creases in 
children lack pigmentation.  
 
 Facial pallor varies with skin pigmentation and presence of edema. 
  
 A mid-systolic „flow‟ murmur, chiefly in the pulmonary area, is 
appreciated when the degree of anemia increases, reflecting increased 
blood flow across heart valves. Systolic bruits and postural hypotension 
may be noted with moderate to severe anemia.  
 
Severe anemia is characterized by a high output state with an elevated pulse 
pressure and a „collapsing‟ pulse. Anemia may participate heart failure even with a 
normal cardiovascular system. 
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IRON 
The total content of iron in an adult body is 3- 5 g. About 70% of this occurs in 
the erythrocytes of blood as a constituent of hemoglobin. At least 5% of body iron is 
present in myoglobin of muscle. Heme is the most constituent of several 
proteins/enzymes (hemoproteins)- hemoglobin, myoglobin, cytochrome, xanthine 
oxidase, catalase, tryptophan pyrrolase, peroxidase. 
 
Functions of iron in the body 
1. Iron mainly exerts its functions through the compounds in which it is present. 
Hemoglobin and myoglobin are required for the transport of o2 and co2. 
2. Cytochromes and certain non- heme proteins are necessary for electron transport 
chain and oxidative phosphorylation. 
3. Peroxidase, the lysosomal enzyme, is required for phagocytosis and killing of 
bacteria by neutrophills. 
4. Iron is associated with effective immunocompetence of the body. 
 
Daily Iron requirement in different age groups: 
 Pregnant and lactating females – 40mg/day 
 Females 11 years to 30 years – 18mg/day 
 Adults males  - 10mg/day 
 Males 11 years to 17 years – 12mg/day 
 Upto 10 years (M/F)  - 10mg/day 
 Full term infants  -  1mg/kg/day from 4 months of age 
 LBW babies   -  2/mg/kg/day from 2 months of age 
 Babies 1000to 1500 grams – 3mg/kg/day from 2 months of age 
 Less than grams  -  4mg/kg/day from 2 months of age 
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IRON SOURCES 
Rich sources 
 Muscle meat 
 Organ meat(liver, heart, kidney) 
 Beef liver 
 
Good sources 
 Greens 
 Leafy vegetables 
 Nuts 
 Cereals 
 Wheat germs 
 Fish 
 Shellfish 
 Poultry 
 Egg 
 Iron fortified cereals and foods 
 Apples and dry fruits 
 Jaggery 
 Yeast 
 Molasses 
 Oysters 
 
Poor sources 
 Wheat  
  Polished rice 
 Milk 
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IRON METABOLISM 
Absorption, transport and storage 
Iron is mainly absorbed in the stomach and duodenum. In normal people, about 
10% of dietary iron is usually absorbed. However, in iron deficient individuals and 
growing children, a much higher proportion of dietary iron is absorbed to meet the 
increased body demands. 
Iron is mostly found in the foods in ferric form (fe3+), bound to proteins or 
organic acids. In the acid medium provided by gastric HCL, the fe3+ is released from 
foods. Reducing substances such as ascorbic acid(vitamin C) and cysteine convert ferric 
iron(Fe3+) to ferrous form(Fe2+). Iron in the ferrous form is soluble and readily 
absorbed. 
 
Factors affecting iron absorption 
1. Acidity, ascorbic acid, alcohol, fructose and cysteine  promote iron absorption. 
2. In iron deficiency anemia, iron absorption is increased to 2-10 times that of 
normal 
3. Small peptides and amino acids favour iron uptake. 
4. Phytate (found in cereals) and oxalate (found in vegetables) interfere with iron 
absorption. 
5. A diet with high phosphate content decreases iron absorption while low phosphate 
promotes. 
6. Impaired absorption of iron is observed in malabsorption syndromes such as 
steatorrhea. 
7. In patients with partial or total surgical removal of stomach and/or intestine, iron 
absorption is severely impaired. 
 
Iron in mucosal cells 
The iron (Fe2+) entering the mucosal cells by absorption is oxidized to ferric 
form (Fe3+) by the enzyme ferroxidase. Fe3+ then combines with apoferritin to form 
ferritin which is the temporary storage form of iron. From the mucosal cells, iron may 
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enter the blood stream(which mainly depends on the body needs) or lost when the cells 
are desquamated. 
 
Transport of iron in the plasma 
            The ironliberated from the ferritin of mucosal cells enters the plasma in ferrous 
state. Here, it is oxidized to ferric form by a copper-containing protein, ceruloplasmin 
which possesses ferroxidase activity. Another cuproprotein ferroxidase 2 also helps for 
the conversion of Fe2+ to Fe3+. 
 
         Ferric iron then binds with a specific iron-binding protein, namely transferring or 
siderophilin (a glycoprotein with mol.wt.90,000). Each transferring molecule can bind 
with two atoms of ferric iron (Fe3+). The plasma transferring (concentration 250mg/dl) 
can bind with 400mg of iron/dl plasma. This is known as total iron binding capacity 
(TIBC) of plasma. 
 
Storage of iron 
Iron is stored in liver, spleen and bone marrow in the form of ferritin. In the 
mucosal cells, ferritin is the temporary storage form of iron. A molecule of 
apoferritin(mol.wt.500,000) can combine with  4,000 atoms of iron. The maximum iron 
content of ferritin on weight basis is around 25%. 
 
Hemosiderin 
           Hemosiderin is another iron storage protein which can hold about 35% of iron by 
weight. Hemosiderin  accumulates  in the body(spleen, liver) when the supply of iron is 
in excess of body demands. 
 
Iron is a one-way substance 
             Iron metabolism is unique as it operates in a closed system. It is very efficiently 
utilized and reutilized by the body. Further, iron losses from the body are minimal which 
may occur through bile, sweat, hair loss etc. Iron is not excreted into urine. Thus, iron 
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differs from the vitamins or other organic and inorganic substances which are either 
inactivated or excreted during the course of metabolic function. Hence, iron is 
appropriately regarded as a one-way substance. 
 
            Iron entry into the body is controlled at the absorption level, depending on the 
body needs. Thus the periodical blood loss in menstruating women increases its 
requirements. Increased iron demands are also observed in pregnancy, lactation, and in 
growing children. 
 
IRON DEFICIENCY ANEMIA 
Iron deficiency anemia occurs when the decrease in total iron body content is 
severe enough to diminish erythropoiesis and cause anemia. The numbers are staggering ; 
2 billion – over 30% of the world‟s population – are anemic, many due to iron deficiency. 
The major factors which influence its prevalence includes  poor socio-economic status, 
low dietary intake, poor accessibility to healthcare facilities and worm infestation in the 
population. 
 
Iron requirements during childhood 
            Understanding of iron requirements, intakes and bioavailability is essential to 
explain the vulnerability of some individuals to develop iron deficiency anemia. 
 
           The iron released from the senescent, red cells during the first 8- 12 weeks of 
life(a period of quiescent erythropoiesis) is stored in the body and helps to maintain 
erythropoiesis upto 4-6 months in a normal term infant and upto 2-3 months in low birth 
weight infant. Normal infants at birth have about 75 mg of iron per kg body weight, two 
thirds of which is present in red blood cells. Infants and children should continue to 
absorb 0.8 to 1.0 mg of iron daily to reach the adult body stores of 4-5 gms. 
 
        Normal body losses of iron are about 20µg/kg/day and most of these losses occur by 
the shedding of cells from intestinal mucosa. These losses are small and are relatively 
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constant but may increase many folds in the presence of diarrhea, dysentery, and parasitic 
infections. 
        Certain factors protect infants from becoming iron deficient in first few months of 
life. These includes 
 Preferential delivery of iron to the fetus during the pregnancy particularly during 
last three months of gestation 
 Placental transform to the newborn immediately after birth when the cord is 
allowed to pulsate before being clamped. 
 Exclusive breast feeding for first four to six months of life, due to better 
bioavilability of iron from the breast milk. 
 
Structures of the red corpuscles in IDA 
         In iron deficiency anemia, the red blood corpuscles are decreased or normal in the 
number and hemoglobin content of the red blood corpuscles is reduced. In the smear, the 
red  cells appear pale with a large central pale area and many of the red blood cells appear 
to be smaller than the normal. This type of anemia is called “hypochromic and 
microcytic anemia” 
 
Etiology 
The etiology varies with the age, sex and country of residence of the patient 
 
Etiological factors in iron deficiency anemia 
1. Increased physiological requirement 
Rapid growth- infants and preadolescence 
Menstruation 
Pregnancy 
2. Decreased  iron stores 
Preterms 
Small for dates 
Twins 
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3. Decreased iron assimilation 
Iron poor diet 
Iron malabsorption 
Sprue 
Pica 
GI surgery 
Chronic diarrhea 
Delayed weaning 
Malnutrition 
 
4. Blood loss 
Gastro intestinal bleeding 
Milk induced enteropathy 
Peptic ulcer disease 
Inflammatory bowel disease 
Drugs- salicylates 
Hook worm infestation 
Fetal Maternal transfusion 
Iatrogenic 
Bleeding diasthesis 
Repeated venous sampling 
 
5. Increased demands 
Prematurity 
Low birth weight 
Recovery from PEM 
Adolescence 
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 Iron poor diet 
 Dietary inadequacy is present in more than 80 % of cases especially in the 
poorer groups. This is still encountered in privileged societies under the 
following circumstances. 
 Infants are also at high risk because the diet predominantly milk contains 
very small amounts of iron. Human milk provides only about 0.3mg / litre of 
iron. 
 Premature babies have only lesser amount of storage iron in the liver as well 
as body 
 Children especially during the early years of life have a need for dietary iron 
to accommodate growth and expansion of the blood volume. 
 
 Iron malabsorption 
 Iron malabsorption is an unusual cause of iron deficiency where 
malnutrition is rampant however both histologic and functional 
abnormalities of the intestine are common. Defective iron absorption is 
caused by non- tropical sprue. 
 Partial or total gastrectomy impairs iron absorption caused by reduction in 
gastric acidity and acceleration of the food through the upper portion of 
the small bowel. The absorption of both haem iron and non-haem is 
defective. 
 Pica or the habitual ingestion of non-food substances is common in 
children and pregnant women. It markedly inhibit iron absorption. 
 Pancreatic enzymes may contribute to the high incidence of iron 
deficiency in patients with cystic fibrosis. 
 
 Gastro intestinal bleeding 
 Hookworm infestation (Ankylostomiasis) is the most important cause of 
intestinal blood loss worldwide. The parasites Ankylostoma duodenale 
and Nectar americanus attach to the proximal portion of the small intestine 
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and suck blood from submucosal vessels. The amount of blood lost is a 
function of the hookworm load, which in turn is proportional to the 
number of ova in the stool. Each worm has been in the intestine for 
months or years, draws, 0.2-0.5 ml of blood per day. It has been estimated 
that the loss of hemoglobin for every twelve worms may be one percent. 
Fecal ova counts in excess of 5000/g are regularly associated with iron 
loss of more than 3 to 4 mg/day and a high incidence of iron deficiency 
anemia. 
 Milk induced enteropathy associated with occult Gastrointestinal bleeding 
has been implicated as the cause of iron deficiency in some infants. 
 During the first year of life, meckel diverticulum is a well- recognized 
cause of asymptomatic bleeding in adult men and postmenopausal women, 
occult bleeding from the gastrointestinal tract is the most common cause 
of iron deficiency. 
 Gastrointestinal bleeding also is prevalent among iron deficiency infants 
and children. Characteristically gastro intestinal bleeding is occult and 
unsuspected. 
 Peptic ulcer disease is a well – documented cause of occult blood loss. 
 Crohn‟s disease and ulcerativecolitis also are commonly associated with 
iron deficiency. 
 Corticosteroids, Indomethacin and other non- steroidal  anti-inflammatory 
agents may also induce gastrointestinal tract bleeding. 
 
Pathogenesis 
               Iron deficiency anemia develops when iron supply to the bone marrow is 
insufficient for the erythropoiesis. 
 
                It has been stated that the body is normally in a state of positive iron balance. 
When a negative iron balance occurs due to either blood loss, increased requirements or 
impaired absorption, the deficit is made good by iron mobilized from the tissues and an 
adequate supply of iron for haemoglobin formation is maintained. It is only when the 
63 
 
tissue stores are exhausted that the supply of iron to the marrow for haemoglobin 
synthesis becomes inadequate and hypochromic anemia develops. Thus iron deficiency 
may be regarded  as developing two stages. 
 
 The progressive depletion and cumulative  exhaustion of the available tissue iron 
stores 
 Iron deficiency state, which may be divided into three distinct stage of severity. 
 
Stage Manifestation 
Early stage Storage iron depletion 
Second stage Iron limited erythropoiesis 
Third stage Iron deficiency anemia 
 
 
Stages of iron deficiency anemia 
1. Storage of iron Depletion 
Iron reserve is small or absent and is characterized by reduced serum ferritin or 
reduced iron concentration in marrow and liver tissue. Haemoglobin and serum 
iron, Transferritin concentration and saturation are within normalimits. 
 
2. Iron limited Erythropoiesis 
Haemoglobin(Hb) may still be normal but serum iron is low and TIBC increased 
with a low serum ferritin and raised free erythrocyte protoporphyrin(FEP) 
 
3. Iron deficiency anemia 
The flow of iron to erythoid marrow is impaired to cause reduction in 
haemoglobin concentration with a progressive microcytic hypochromic anemia 
associated with reduced serum iron, transferring saturation and serum ferritin 
level. 
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Role of iron deficiency anemia in various systems 
Cardiovascular system 
         Dyspnoea and palpitation are common symtoms while on exertion but in very 
severe anemia the patient may get cardiac failure and there may br dyspnoea at rest. 
Haemic murmurs are commonlyheard in anemic patients. The murmurs are most often 
mild systolic murmurs heard at the mitral area. 
            Systolic bruits over the carotid arteries in the neck are sometimes present in 
anemia usually they are bilateral and occur in the absence of an aortic systolic bruit and 
disappear following correction of the anemia. Jugular venous pressure increase in severe 
anemia due to high pulse pressure with a capillary pulsation. Oedema of the legs 
occasionally occurs in ambulant patient with severe anemia as the result of venous 
capillary pressure on exertion and increased capillary permeability. 
 
Central nervous system 
        Symptoms include faintness, giddiness, headache, roaring in the ears, tinnitus, spots 
before the eyes, lack of concentration, drowsiness and with severe anemia clouding of 
consciousness, numbness and sometimes tingling of the hands and feet. 
 
Productive system 
    Menstrual disturbances are commonly associated with anemia 
 
Renal system 
     Slight proteinuria may be present with severe anemia. Anemia may further reduce 
renal function at which nitrogen retention develops; correction of anemia in such patient 
is usually followed by a fall in blood urea. 
 
Gastro intestinal system 
        Anorexia is the commonest symptom, nausea, flatulence and constipation may 
also occur. Slight to moderate smooth hepatomegaly is common in severe anemia and 
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when congestive cardiac failure develops. The liver may become tender. In certain cases 
of iron deficiency anemia spleen may be enlarged. 
 
Pyrexia 
     Mild pyrexia may occur with severe anemia but marked fever is due to either the 
causative disorder or due to some complicating factor. 
 
Signs 
 Pallor of skin, mucous membrane, palms, nailed and conjunctiva 
 Koilonychia 
 Tachycardia 
 Smooth, pale, glossy palate 
 High volume pulse 
 Systolic murmurs 
 Cardiomegaly 
 Splenomegaly in rare cases. 
Symptoms 
 Weakness 
 Fatigue 
 Exercise intolerance 
 Loss of appetite 
 Irritability 
 Lack of concentration 
 Desire to ingest unusual substances like ice or dirt 
 Giddiness 
 Insomnia 
 Constipation 
 Breathlessness on exertion 
 Dimness of vision 
 Tinnitus 
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 Anginal pain 
 Palpitation 
 Parasthesia in fingers and toes 
 Abdominal distension 
 
Complication of iron deficiency anemia 
 In patients with heart disease severe anemia may precipitate angina pectoris or 
congestive heart failure 
 Infections are more common in Iron deficiency anemia, especially those of 
respiratory, gastrointestinal and urinary tracts. 
 
Investigation required for iron deficiency anemia 
1. Blood investigation 
 Total red blood cell count 
 Differential count 
 Erythrocyte sedimentation rate 
 Mean corpuscular volume 
 Mean corpuscular hemoglobin concentration 
 Packed cell volume 
 Peripheral blood smear 
 Red cell survival 
 Serum iron 
 Serum ferritin concentration 
 Serum protein 
 Serum creatinine. 
 
2. Urine investigation 
  Urine sugar 
 Albumin 
 Deposits 
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 Red blood cells 
 Pus cells 
 
3. Stool investigation 
 Occult blood 
 Organisms 
 Ova 
 Cyst 
 Red blood cells 
 Pus cells 
 
4. Special investigations occasionally required 
 X- ray barium meal, X-ray barium enema, X-ray Chest 
 Endoscopy, Colonoscopy, Sigmoidoscopy, Gastroduodenoscopy 
 Isotope studies 
 Skeletal survey for multiple myeloma and secondary deposits 
 Bone marrow examination 
 Liver function test 
 Jejunal biopsy, urography, selective angiography 
 Ultrasonography 
 
DIFFERENTIAL DIAGNOSIS 
1. Anemia of infection 
2. Pyridoxine (vit B6) deficiency anemia 
3. Haemoglobinopathies 
4. Sideroblastic anemia 
5. Anemia of lead poisoning 
DIAGNOSIS 
Following criteria are essential to diagnose Iron deficiency anemia 
 History of inadequate intake of dietary iron and blood loss if any. 
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 Typical symptoms and signs like easy fatiguability, pallor, pica, koilonychias, 
smooth tongue, cheilosis, and dysphagia associated with general comsiderations. 
 Hypochromic and microcytic structure of red blood cells 
 Low serum iron, increased total iron binding capacity. 
 Bone marrow hemosiderin absent 
 Blood loss usually occult 
 Platelet count is either normal or raised 
 Hemoglobin estimation variably reduced 
 Reduced mean cell volume 
 Erythrocyte count may be normal or reduced 
 Serum ferritin level is reduced 
 
MANAGEMENT 
    Management of IDA is considered by three methods 
1. Correction of anemic state 
2. Replenishment of iron stores 
3. Elimination of the cause 
 
PROPHYLAXIS 
The main principles in the prevention of nutritional Iron deficiency anemia are, 
1. The regular consumption of a well balanced diet containing an adequate quantity 
of iron 
2. The periodic administration of iron as drug during increased physiological needs 
such as rapid growth during infancy and preadolescence, pregnancy, lactation and 
menstruation. 
3. Maintenance of a normal hemoglobin level in the mother for the prevention of 
iron deficiency anemia in infants. Premature and unduly small infants should be 
given prophylactic iron as a routine therapy. Iron rich sources should be added in 
the infants diet from the third or fourth month and thereafter be progressively 
increased.  
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PREVENTION OF IDA 
The basic approaches to the prevention of IDA include 
1. Protection and promotion of breast- feeding for as long as possible along with 
timely weaning is effective in preventing IDA Low birth weight infants need iron 
supplementation from the age of 2 months. 
2. Dietary modification and consumption of larger amounts of habitual foods 
increases total iron consumption by 25- 30 percent. Processes like germination, 
consumption and green leafy vegetables would be additional long-term methods 
for prevention of IDA. 
3. Periodic deworming with anti-helminthic drugs for hookworm infestation and 
schistosomiasis  should be considered in endemic areas. 
4. Supplementation with medicinal iron is considered necessary to reduce the extent 
of anemia in developing countries. 
5. Food and salt fortification with iron are evolving rapidly and would be one of the 
most effective ways to control IDA. Salt fortification gives an iron content of 1 
mg per gram of salt in the preparation. 
 
DIET 
Haem iron sources 
 Muscle meat (red more than white) 
 Organ meat(e.g Liver) 
 Fish and shellfish 
 Poultry 
 
Non-haem iron sources 
 Oatmeal 
 Nuts 
 Pulses 
 Dried fruit 
 Whole meat 
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 Bread, eggs 
 Green leafy vegetables 
 Iron fortified cereal foods 
 Jaggery and yeast 
 Foods rich in vitamin C enhance iron absorption. 
 
Self care procedures for Iron deficiency anemia 
1. Eat more foods that are good sources of iron 
2. Concentrate on green leafy vegetables, red meat, beef liver, poultry, fish, wheat 
germ, oysters, dried fruit, and fortified cereals 
3. Foods high in vitamin C like citrus fruits, tomatoes and strawberries help the body 
absorbing iron from food 
4. Red meat not only supplies a good amount of iron, it also increases absorption of 
iron from other food sources 
5. Take an iron supplement 
6. Increased dietary fibre to prevent constipation 
7. Avoid aspirin and products with aspirin 
8. Eat fresh uncooked fruits and vegetables often. Don‟t overcook food that destroys 
folic acid. 
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MATERIALS AND METHODS 
 
To find the efficacy of Pandu Noikku Kalappu Thool, the following studies were 
carried out in the present investigation. 
I. Collection, Identification and confirmation of the raw drugs, for the 
preparation of trail drug 
II. Preparation of trail drug 
III. Biochemical analysis of trail drug 
IV. Pharmacological studies of trail drug. 
V. Clinical trail 
        The clinical study on “Pandu Noi” is being conducted in the outpatient and inpatient 
postgraduate department of Kuzhanthai Maruthuvam at Government Siddha Medical 
College Palayamkottai. 
Selection of cases 
   Patients reporting with symptoms of inclusion criteria will be subject to screening 
test and documented using screening proforma. 20 inpatients and 20 outpatients are 
select. In patients will be given medicine and provided hospital diet. Outpatients provide 
medicine and dietary regulations. 
Inclusion criteria 
 Age  : 5 to 13 years 
 Sex  : Both male and female children 
 Hb  level between 6-10 gms. 
 Pallor of skin and mucous membrane 
 Lassitude. 
 Fatigue 
 Anorexia 
 Irritability 
 Worm infestation 
 Anemia due to iron deficiency. 
 Families with poor economic status 
 Having perverse taste to eat mud, sand, ash, etc or increased food cravings 
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 Brittle nails 
 Shortness of breath 
 Palpitation 
 Patients willing to give blood and urine sample for lab investigations whenever 
required 
 Informed written consent given by parents/guardian of the patients. 
Exclusion criteria 
 Hb less than 6 
 Patients with chronic infection 
 Morethan age of 14 years 
 Renal and liver diseases 
 Bleeding disorder 
 Malignancy of any type(Thalassemia major, Aplastic anemia, Sicklecell anemia, 
Hemolytic anemia) 
 Rheumatic fever 
 Nephrotic syndrome 
 Tuberculosis 
Withdrawal criteria 
 Occurrence of any adverse reactions 
 Patients turned unwilling to continue in the course of clinical trial 
 Poor patient compliance 
Study of clinical diagnosis 
    A case sheet was prepared on the basis of Siddha methodology and modern 
methodology to diagnose the disease. An individual case sheet was maintained for each 
and every patient. 
   A complete history of the patient was taken. Name, Age, Sex, History of present 
and past illness, Antenatal, Neonatal and postnatal history, personal and dietetic history, 
family history and Socio-economic status were noted. 
      Siddha diagnosis was made on the basis of Envagai thervugal, Mukkutram and 
Ezhu udalkattukal. 
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    Modern diagnostic methods were adopted with the consultation of pediatric 
professor. 
Tests and assessments 
 Siddha tests and assessment 
Mukuttram 
Udal kattukal 
Envagai thervugal 
Neerkuri 
Neikuri 
 Clinical assessment 
Pallor of skin and mucous membrane 
Lassitude 
Fatigue 
Palpitation 
Tachycardia 
Heamic murmur 
Angular stomatitis 
 
 Laboratory assessment 
The Modern diagnostic tests such as blood test for TC, DC, ESR, Hb, 
PCV, MCV, MCH, MCHC, Peripheral blood smear, etc., urine analysis for 
albumin, sugar, deposits, etc., and stool examination for ova, cyst, occult blood to 
rule out any existing illness. 
   Hemoglobin was estimated before and after therapy. 
 
Administration of Trial Medicine: 
  The trial drug was prepared carefully. 
    Before starting the treatment deworming was done with Nilavagai choornam – 
3gms Od at night with hot water for 3-5 days. “Pandu noikku kalappu thool” with the 
adjuvant of honey or ghee after food intake was given to all the 40 patients three times a 
day during their treatment period. 
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    The Biochemical analysis of trial drug was carried out in the biochemical 
laboratory and the haematinic effect, hepato protective and laxative action of the drug 
was tested in the pharmacological laboratory. 
   Analysis of observations made from the 40 patients with signs and symptoms of 
the disease were recorded. In addition to medicine the patients were advised to take iron-
rich diet and to attend the out patients department for follow up. 
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PREPARATION AND REVIEW OF TRIAL MEDICINE 
 
kUe;jpd; ngah; - ghz;L Neha;f;F fyg;Gj; J}s; 
         “ngUq;fhak; trk;Grpj; jpu%uk; Rf;F  
          NgRkrNkhjfq; fLf;fha; jphpgiyAq; Nfh~;lk; 
          kUe;jhd jpitailNt ahj;jpg; gpj;J  
          kjpahky; nghbj;J ul;br; rPdp$l;br; 
          RUq;fhky; %tpuyh ys;sp Kf;fhy; 
          Rj;jkha; nea; Fioj;J tpOq;FtPNuy; 
          tUe;jhk ypUf;f Ykhk; thjgpj;jQ; 
          raNuhfk; ghz;LUTq; flypy; NghNk” 
 
NrUk; ruf;Ffs; 
1. ngUq;fhak;   - 100fpuhk; 
2. trk;G        - 100 fpuhk; 
3. rpj;ju%yk;   - 100 fpuhk; 
4. Rf;F         - 100 fpuhk; 
5. mrkjh Xkk; - 100 fpuhk; 
6. fLf;fha;     -  100 fpuhk; 
7. ney;ypf;fha;  - 100 fpuhk; 
8. jhd;wpf;fha;  - 100 fpuhk; 
9. Nfhl;lk;      - 100 fpuhk; 
10. rh;f;fiu      - 1800 fpuhk; 
nra;Kiw 
      ruf;Ffis Rj;jp nra;J #uzpj;J vLj;Jf; nfhz;Nld;. 
msT 
     500 kpfp - 2 fpuhk; tajpw;Nfw;g 
JizkUe;J 
      Njd;> gRnea; 
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jPUk; Neha; 
      ghz;L> Mkthjk;> gpj;jNjhlk;> vd;GUf;fp Mfpait jPUk;. 
Mjhu E}y; 
       Njiuah; thflk;. gf;fk; - 118 
 
ngUq;fhak; 
OTHER NAME     : mj;jpahfpufk;> ,q;F> ,uzk;> ty;yPfk>; ,uhklk;>  
                         fe;jp> fhak;>   re;Jehrk;> G+jehrk; 
BOTANICAL NAME   : Ferula asafoetida 
FAMILY                        : Apiaceae 
PART USE  
SUVAI                            : ifg;G fufug;G 
THANMAI                     : ntg;gk; 
PIRIVU                           : fhh;g;G 
 
nghJFzk;  :  
       “je;jNt je;j %yj;njOk;gpzp 
          rUtfhsk; tpUr;rpfq;fPlk;kh 
       ke;jk; thjk; cjuth;j;jk; my;Fy;Neha; 
          khh;gzq;fl;l Fd;kk; kNfhjuk; 
       ce;J nfh;g;gj;jpd; tpj;jpuQ; #iyr;#h; 
          cjpug;G+r;rp rpNyj;Jkj;JWk; typ 
       te;jnka;f;fLg; Nghbit Kw;WNk 
          khA ehWew; fhaq;fpilf;fpNd” 
 
 
MEDICINAL USE 
        Foe;ijfs; tapw;wpYz;lhFk; G+r;rpfis ntspg;gLj;j ,ij ePhpypl;L 
miuj;Jf; fyf;fp gPr;rhfg; gad;gLj;jyhk;. 
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ACTION 
 Stimulant 
 Carminative 
 Antispasmodic 
 Expectorant 
 Laxative 
 Anthelmintic 
 Diuretic 
 Aphrodisiac 
 Emmenagogue 
 
ACTIVE CONSTITUENTS 
 Resin 
 Gum 
 Volatile oil 
 Asaresinotannol 
 
 CHEMICAL CONTITUENTS 
                 An analysis of asafoetida shows it to consist of carbohydrates 67.8% per 100 
gms, moisture 16.0%, protein 4.0%, fat 1.1%, minerals 7.0% and fiber 4.1%. Its mineral 
and vitamin contents include substantial calcium besides phosphorus, iron, carotene, 
riboflavin and niacin. Its calorific value is 297, contains 40-64% resinous material 
composed of ferulic acid, umbel-liferone, asaresinotannols, farnesiferols A, B, and C etc., 
about 25% gum composed of glucose, galactose, l-arabinose, rhamnose, and glucuronic 
acid and volatile oil (3-17%) consisting of disulfides as its major components, notably 2-
butyl propenyl disulfide (E- and Z-isomers), with monoterpenes (α- and β-pinene, etc.), 
free ferulic acid, valeric acid, and traces of vanillin (LAF). The disagreeable odor of the 
oil is reported to be due mainly to the disulphide C11H20S2. 
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trk;G 
OTHER NAME  : cf;fpuk;> trk>; tir> Ntzp> RLthd;> ciug;ghd;>  
                         Ngh; nrhy;yh kUe;J> gps;is kUe;J. 
BOTANICAL NAME : Acorus calamus 
FAMILY                      : Araceae 
PART USE                  : Root 
SUVAI                         : Karppu 
THANMAI                  : Veppam 
PIRIVU                       : Karppu 
 
nghJFzk; 
       ‘ghk;ghjp eQrhw; Gjg;Gz; typtplghfq; Fd;kk; 
        #k;gh hpj;jgpj; jk;Kf ehw;wk;td; #iyrd;dp 
        tPk;ghk;ig fhrk; gPypfQ; rpypgjk; tPwpUky; 
        jhk;gdq; fpUkp apitNaF khrpt rk;gpidNa” 
 
MEDICINAL USE 
    trk;gpdhy; vy;yh eQ;Rfs;> Gz;tiffs;> Itiftyp> Fd;kk;> ,uj;jgpj;jk;> 
tha;ehw;wk;> #iy> Kg;gpzp> ,Uky;> <uy; Neha;fs>; ahidf;fhy;> ehlhg;GO 
Mfpaitg; Nghk;. 
ACTION 
 Stimulant 
 Stomachic 
 Antiperiodic 
 Carminative 
 Nauseant 
 Emetic 
 Disinfectant 
 Germicide 
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CHEMICAL CONSTITUENTS 
    The drug contains 1.5 to 3.5 % of volatile oil, starch, resin(2.5%) and 
tannin(1.5%). Volatile oil contains asaraldehyde. The other contents of the oils are 
asarone and eugenol. Calamus also contains a bitter amorphous principle known as 
acorine.  
 
rpj;jpu %yk; 
OTHER NAME  : rptg;Gr; rpj;jpu%yk;> nfhbNtyp> nrq;nfhbNtyp 
BOTANICAL NAME : Plumbago rosea 
FAMILY                      : Plumbaginaceae 
PART USE                  : Root 
SUVAI                         : Karppu 
THANMAI                  : Veppam 
PIRIVU                       : Karppu 
 
nghJFzk; 
   ,J fgk;> tPf;fk;> fpufzp> thjk;> tapw;Wg;GO> ghz;L Kjypatw;iwAk; #iy> 
tha;T> Rfrd;dp> ke;jRuk>; jiyNeha; MfpaitfisAk; fz;bf;Fk;. 
ACTION 
 Stimulant 
 Rubefacient 
ALKALOID 
 Plumbagin 
 Sitosterol 
 Glycoside 
 
Rf;F 
OTHER NAME : mUf;fd;> mjfk;> Mh;j;ufk;> cgFy;yk;> cyh;e;j ,Q;rp>  
                      RLgj;jpk;> Rz;b> nrhz;b> nrsgd;dk;> nrsth;zk;> etRW>  
                      ehfuk;> knes\jk;> tpr;t Ng\[k;> tpl%ba mkph;jk;>  
                      Nth;f;nfhk;G. 
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BOTANICAL NAME : Zingiber officinale 
FAMILY                      : Zingiberaceae 
PART USE                  : Dried Rhizome 
SUVAI                         : Karppu 
THANMAI                  : Veppam 
PIRIVU                       : Karppu 
 
nghJFzk; 
“#iy ke;jk; neQ;nrhpT NjhlNkg; gk;koiy 
  %yk; ,iug;gpUky; %f;FePh; - thyfg 
 Njhlkjp rhue; njhlh;thj Fd;kePh; 
  Njhlk; Mkk;Nghf;FQ; Rf;F” 
 
ACTION 
 Stimulant 
 Stomachic 
 Carminative 
ALKALOID 
 Volatile oil 
 Zingiberene 
 Curcumene 
 Resin 
 Gingerol 
 Shogaols 
 Gingediols 
 Gingerone 
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mrkjh Xkk; 
OTHER NAME : mrk; jhfk;> mrk;jh Xkk; 
BOTANICAL NAME : Trachyspermum roxburghianum 
FAMILY                      : Umbelliferae 
PART USE                  : Dried seed 
SUVAI                         : Karppu 
THANMAI                  : Veppam 
PIRIVU                       : Karppu 
 
nghJFzk; 
“rPjRuq; fhrQ; nrhpahke; jk;nghUky; 
Ngjpapiur; ry;fLg;G Nguhkk; - XjpUky; 
gy;nyhLgy; %yk; gfkpitNeh nad;nrANkh 
nrhy;nyhLNghk; Xknkdr; nrhy;”. 
 
 
MEDICINAL USE 
  IaRuk;> ,Uky;> nrhpahke;jk;> nghUky;> fopr;ry;> Cop> Flypiur;ry;> ,iug;G> 
gy;Neha;> Fa;aNuhfk; ,itfs; Nghk;. 
ACTION 
 Stomachic 
 Antispasmodic 
 Carminative 
 Antiseptic 
 Stimulant 
 Tonic 
 Sialogogue 
CHEMICAL CONSTITUENTS 
      Ajowan fruits contain 2-4% of volatile oil, about 21% fat, 17%  proteins and 25% 
carbohydrates. Traces of tannin, Glycoside and steroidal substances have been reported. 
Volatile oil mainly contains thymol(35-60%), p-cymene(50-55%), terpinene (30-35%). 
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Nfhl;lk; 
OTHER NAME : Nfh~;lk;> Fuh> xyp 
BOTANICAL NAME  : Costus speciosus 
FAMILY                       : Costaceae 
PART USE                    : Root 
SUVAI                           : Kaippu, viruviruppu 
THANMAI                    : Veppam 
PIRIVU                         : Karppu 
 
nghJFzk; 
  “ehl;bYW ntl;il eLf;fk; vDNeha;fs; 
   Nfhl;lnkdr; nrhd;dhy; FiyAq;fhz; - $l;bw; 
  RuNjhle; njhz;ilNeha; Njhyhj gpj;jk; 
   guNjrk; NghNk gwee;J” 
 
MEDICINAL USE 
   fz;> jhil> tapW. fOj;J> jiy eh tha;> ,t;tplj;jpYz;lhFk; Neha;fs;> 
Ruk;> mijg;G> thA> Gz;> ,iug;G> vyp> ghk;G Kjypaitfspd; eQ;Rfs;> 
Nkff;fl;b> gapj;jpak; ,itg; Nghk;. 
ACTION 
 Stomachic 
 Expectorant 
 Tonic 
 Stimulant 
 Diaphoretic 
ALKALOID 
Tigogenin and diosgenin from rhizomes (2.6% diosgenin) and stems have been 
isolated. a-amyrin stearate, b-amyrin and lupeol. Palmitates from leaves have been 
isolated. 
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fLf;fha; 
BOTANICAL NAME : Terminali chebula 
FAMILY                      : Combretaceae 
PART USE                   : Dried fruit 
SUVAI                          : Thuvarppu, Inippu, Pulippu, Karppu, Kaippu 
THANMAI                   : Veppam 
PIRIVU                        : Inippu 
 
nghJFzk; 
“jhil fOj;jf;fp jhY Fwpaptplg; 
  gPil rpypgjKw; NgjpKlk; Milnal;lhj; 
 J}ykpo Gz;thj Nrhzp fhkhiy apuz; 
  lhykpo Nghk; thpf;fhahy;” 
 
MEDICINAL USE 
fLf;fhapdhy;> fd;dk;> fOj;J> eh> Mz;Fwp ,t;tplq;fspy; Vw;gLk; Neha;fs;> 
fhybg;Gw;W Neha;> mjpJ}yk;> thjRNuhzpjk;> fhkhiy> rq;fktplq;fs; Nghk;. 
ACTION 
 Purgative 
 Astringent 
 Tonic 
ALKALOID 
 Chebulosides 
 Gallic acid called chebulin 
 Ellagic acid 
 Chebulinic acid 
 Ethyl gallate 
 Puniclagin 
 Tannic acid 
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ney;ypf;fha; 
OTHER NAME : ney;yp> Mk;gy;> kpUJgyh> Mkyfk; 
BOTANICAL NAME : Phyllanthus emblica 
FAMILY                      :  Euphorbiaceae 
PART USE                  :  Dried fruit 
SUVAI                         :  Pullipu, Thuvarppu, Inippu. 
THANMAI                  : Thatpam 
PIRIVU                       : Inippu 
 
nghJFzk; 
“gpj;j kdiyak; gPerk;tha; ePh;the;jp 
  ke;jkyf; fhLk; kaf;fKkpy; - xj;jTU 
 tpy;ypf;fhak; kUq;fh nkd;dhl;fhye; Njh;e;j 
ney;yp fhak; kUe;JzP” 
 
MEDICINAL USE 
tha;ePh; Rug;G> the;jp> kaf;fk;> jiyRw;wy;> kyge;jk;> gpuNkfk; ,itNghk;. 
 
ACTION 
 Astringent 
 Refrigerent 
 Luxative 
ALKALOID 
 Ascorbic acid 
 Emblicanin 
 Puningluconin 
 Amarulone 
 Phyllanthusin 
 Amariin 
 Phyllanthin 
 Isolintetralin. 
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 Tannin 
 Gallic acid 
 Flavonoids. 
 
jhd;wpf;fha; 
OTHER NAME : mKjk;> rjfk;> jpwpypq;fk;> jhdpf;fha; 
BOTANICAL NAME  : Terminalia bellerica 
FAMILY                       : Combretaceae 
PART USE                   : Dried fruit 
SUVAI                          : Thuvarppu 
THANMAI                   : Veppam 
PIRIVU                        : Inippu 
 
nghJFzk; 
rpye;jptplk; fhkpag;Gz; rPohd Nkfq; 
fye;JtUk; thjgpj;jq; fhNyh „ lyh;e;Jlypy; 
Cd;wpf;fha; ntg;g Kjpugpj;Jq; fuf;Fe; 
jhd;wpf;fhA; ifapnyLj; jhy; 
 
MEDICINAL USE 
rpye;jpeQ;R> Mz;Fwpg; Gz;> nts;is> FUjpaoyp Neha;> thjgpj;j Neha;fs; 
Nghk;. 
ACTION 
 Astringent 
 Expectorant 
 Laxative 
 Tonic 
ALKALOID 
 Beta- sitosterol 
 Gallic acid 
 Chebulinic acid 
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 Ellagic acid 
 Quinic acid 
 Tannase 
 Polyphenol oxidase 
 Ascorbic oxidase 
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OBSERVATIONS AND RESULTS 
 
For this clinical study 20 cases were selected and treated in the Inpatient ward and 
20 cases treated in the out-patient ward of P.G Department of Kuzhanthai Maruthuvam, 
Govt. Siddha Medical College, Palayamkottai. 
 
 Results were observed with respect to the following criteria. 
1. Age 
2. Sex 
3. Religion 
4. Family History  
5. Socio economic status 
6. Diet  
7. Paruva Kaalam 
8. Mukkutra Kaalam 
9. Thinai 
10. Aetiological factors 
11. Mukkutra Iyal 
12. Ezhu Udal Kattukal 
13. Envagai thervukal 
14. Clinical presentation 
15. Results and treatment 
 
The observations recorded with the above said criteria were given in the tabular column 
form. 
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I. Biochemical analysis 
Biochemical analysis of Pandu Noikku Kalappu Thool prove that it has 
calcium, starch, ferrous iron, tannic acid, unsaturated compounds, reducing sugar, 
amino acid. 
 
II. Pharmacological analysis 
In the Pharmacological studies, the trail drug has haematemic and laxative effects 
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III. CLINICAL TRIALS 
1. Distribution of patients according to Age 
S.No Age Paruvam No. of cases Percentage 
1.  0-6 month Kappu Paruvam   
2.  6-12 month Kappu and Senkeerai Paruvams   
3.  1-3 year Thalaattu, Sappani, Mutham and 
Varugai Paruvams 
  
4.  3-6 years Ampuli, Sitril, Siruparai, 
Siruthaer  viduthal (Male child) 
Ammanai,  Neeraduthal, Oonjal 
(Female child) 
   
            4 
 
    10 
5.  6-12 years Siruparuvam (Male child) 
Pethai and Pethumbai (Female 
child) 
        
            36 
  
    90 
 
Among 40 patients treated 10% cases belonged to 3-6 years and 90% cases belonged  to 
6-12 years. 
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2. Distribution according to the Sex 
 
S.No Sex No. of Cases Percentage 
1.  Male children                20            50 
2.  Female children                20            50 
 
Among the 40 cases selected 50% patients were male children and 50% were female 
children. 
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3. Distribution according to the religion 
 
S.No Religion No.of cases Percentage 
1.   Hindu 19 47.5 
2.  Christian 19 47.5 
3.  Muslim 2 5 
 
Out of 40 cases 47.5 % were Hindus, 47.5% were Christian and 5% were Muslims 
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4. Distribution according to Family history 
 
Sl. No Family history No. of cases Percentage 
1.  Positive 30 75 
2.  Negative 10 25 
 
75% of cases have positive family history. 
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5.  Distribution of patients according to the Socio economic status 
 
S.No Economic status No. of cases Percentage 
1.  Poor 32 80 
2.  Middle 8 20 
3.  Rich - - 
 
Out of 40 patients 80% were poor and 20% were middle class people. 
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6. Distribution according to Dietary habits 
 
Sl. No Diet No. of cases Percentage 
1.  Vegetarian 10 25 
2.  Mixed 30 75 
 
75% of cases have mixed diet and 25% of cases have vegetarian diet. 
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7. Distribution of patients according to Paruva Kaalam 
 
S. No Paruvakaalam No. of cases Percentage 
1.  Kaar (Aavani, Purattasi) _ _ 
2.  Koothir (Iypasi, Karthigai) _ _ 
3.  Munpani (Margali, Thai) 5 12. 5 
4.  Pinpani (Masi, Pankuni) 17 42.5 
5.  Elavenil (Chithirai,Vaikasi) 18 45 
6.  Muthuvenil (Aani,Aadi) _ _ 
 
Among the 40 cases selected 12.5% of cases were admitted in Munpani kaalam, 42.5% of 
cases were admitted in Pinpani kaalam and 45% of cases were admitted in Muthuvenil 
kaalam. 
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8. Distribution according to the Mukkutta Kaalam 
 
S.No Kaalam No. of cases Percentage 
1.   Vatham 40 100 
2.  Pitham - - 
3.  Kapham - - 
 
In this study all the 40 patients were in Vatha kaalam since all the patients belong to 
children. 
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9. Distribution according to Thinai 
 
S.No Thinai No.of cases Percentage 
1.  Kurinji(Hill area) 5 12.5 
2.  Mullai(Forest area) - - 
3.  Marutham(Fertile area) 33 82.5 
4.  Neithal (Costal area) 2 5 
5.  Paalai(Desert area) - - 
 
Among 40 cases 12.5 cases belongs to kurinchi nila, 82.5% belongs to Marutha nilam 
and 5% belongs to Neithal nilam. 
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10. Distribution according to the aetiological factors 
 
S.No Aetiological factors No. of cases Percentage 
1.  Iron deficiency 32 80 
2.  Worm infestation 8 20 
 
Out of 40 cases treated, Iron deficiency is 80%  and Worm infestation is 20% 
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11. Distribution according to the Mukkutra nilai 
 
A. Affected Vatham 
Sl. No Vatham No. of cases Percentage 
1.  Pranan 25 62.5 
2.  Abaanan 15 37.5 
3.  Viyaanan 40 100 
4.  Uthaanan - -- 
5.  Samaanan 40 100 
6.  Naagan - - 
7.  Koorman - - 
8.  Kirukaran 40 100 
9.  Devathathan 40 100 
10.  Thananjeyan - - 
 
Among 10 types of Vaatham, viyanan, samanan, kirukaran and devathathan were 
affected in all 40 cases Pranan affected 62.5% and Abaanan affected 37.5%. 
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B. Affected Pitham 
Sl. No Pitham No. of cases Percentage 
1.  Anar Pitham 40 100 
2.  Ranjagam 40 100 
3.  Sathagam 40 100 
4.  Prasagam 40 100 
5.  Alosagam - - 
 
Among 5 types of pitham anar pitham, ranjagapitham, sathagapitham, 
prasagapitham and alosagam were affected 100% of cases. 
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C. Affected Kabam 
Sl. No Kabam No. of cases Percentage 
1.  Avalambagam 40 100 
2.  Kilethagam 40 100 
3.  Pothagam 40 100 
4.  Tharpagam - - 
5.  Santhigam - - 
 
Among 40 cases avalambagam, kilethagam and pothagam were affected 100% 
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12. Distribution according to Ezhu udal kattukal 
 
Sl. No Udal kattugal No. of cases Percentage 
1.  Saaram 40 100 
2.  Senneer 40 100 
3.  Oon - - 
4.  Kozhuppu - - 
5.  Enbu - - 
6.  Moolai - - 
7.  Sukkilam/Suronitham Not applicable Not applicable 
 
Regarding 7 udal kattukal saaram and senner affected in all 40 patients. 
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13. Distribution according to Envagai thervukal 
Sl. No Envagai thervugal No.of cases Percentage 
1.  Naa 40 100 
2.  Niram 40 100 
3.  Mozhi - - 
4.  Vizhi 40 100 
5.  Malam 18 45 
6.  Moothiram 40 100 
7.  Naadi 
Vathakabam 
Kabavatham 
Kabhapitham 
 
22 
10 
8 
 
55 
25 
20 
8.  Sparisam 10 25 
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14. Distribution according to the clinical presentation 
S.No Signs and Symptoms During Admission 
No of cases 
During Discharge 
No of cases 
1.  Pallor of conjunctiva and 
nail beds 
40 4 
2.  Anorexia 40 - 
3.  Ulceration of mouth 15 - 
4.  Constipation 28 - 
5.  Lassitude 40 5 
6.  Emaciation 10 3 
7.  Palpitation 40 7 
8.  Dyspnoea on exertion 25 6 
9.  Worm infestation 8 - 
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15. Among the 40 cases studied the results were observed as follows. 
 
Sl. No Gradation No. of cases Percentage 
1.  Good 34 85 
2.  Fair 6 15 
3.  Poor Nil - 
 
Among the 40 patoients selected 85% cases showed good response 15% of cases 
showed fair response. 
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IP PATIENT WARD CASHSHEET 
S.No IP. No Name of the patient Age/Sex Signs and symptoms 
Admission 
date 
Discharge 
date 
No .of days 
Results 
 
Treated 
in IP 
Follow up in 
OP 
1 256 Veera lakshmi 2 /Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth. 
2.2.16 2.3.16 29 16 Good 
2 711 Udaya subha 11/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Constipation 
16.3.16 2.4.16 17 30 Good 
3 25764 Sanjay 10/Mc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth, 
Constipation. 
19.3.16 2.4.16 14 35 Good 
4 755 Ramachandiran 12/Mc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation 
19.3.16 2.4.16 14 35 Fair 
5 756 Pechimuthu 12/Mc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth. 
19.3.16 2.4.16 14 30 Good 
6 757 Yovaan 12/Mc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth. 
19.3.16 2.4.16 14 33 Good 
7 30114 Valliappan 11/Mc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation 
2.4.16 9.4.16 7 40 Good 
8 33356 Ansu 12/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth. 
14.4.16 26.4.16 13 30 Fair 
9 30118 Maathavan 11/Mc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Constipation 
2.4.16 9.4.16 7 42 Good 
10 33353 Jeyasheela 12/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation 
14.4.16 26.4.16 13 30 Good 
11 30117 Sudalai 9/Mc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation 
2.4.16 9.4.16 7 35 Good 
12 33355 Parimala 12/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth, 
Constipation. 
14.4.16 26.4.16 13 28 Good 
13 30120 Venmathi 7/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation 
2.4.16 9.4.16 7 40 Good 
14 33354 Mano 12/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth. 
14.4.16 26.4.16 13 44 Good 
15 1064 Sheeba 10/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation 
21.4.16 5.5.16 15 32 Good 
16 1065 Priya 10/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Constipation 
21.4.16 5.5.16 15 35 Good 
17 1066 Vennila 10/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth, 
Constipation. 
21,4.16 5.5.16 15 30 Good 
18 1119 Prema 12/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth. 
27.4.16 14.5.16 17 28 Fair 
19 1120 Sangeetha 12/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation 
27.4.16 14.5.16 17 30 Good 
20 1155 Mercy 12/Fc Pallor of conjunctiva and nail beds, Anorexia, 
Lassitude, Palpitation, Ulceration of mouth, 
Constipation. 
30.4.16 18.5.16 18 35 Good 
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HAEMATILOGICAL INVESTIGATION RESULTS 
S.No 
IP. 
No 
Name of the 
patient 
Age/Sex 
Before Treatment After Treatment 
Hb 
gm% 
RBC 
Mil/cumm 
PCV% MCV MCH 
MCHC  
Gm% 
Peripheral 
Blood 
Smear 
Hb 
gm% 
RBC 
Mil/cumm 
PCV% MCV MCH 
MCHC  
Gm% 
Peripheral 
Blood 
Smear 
1 256 Veera lakshmi 2 /Fc 8.2 3.4 27 75 24 31 H.M 11.6 3.3 26 74 25 32 N 
2 711 Udaya subha 11/Fc 7.6 3.0 25 71 24 31 H.M 11.8 3.2 30 78 25 34 N 
3 25764 Sanjay 10/Mc 8.4 3.7 26 78 25 32 H.M 10.5 3.8 28 79 28 32 N 
4 755 Ramachandiran 12/Mc 8.5 3.2 24 73 21 31 H.M 11.6 3.8 27 76 26 33 HM 
5 756 Pechimuthu 12/Mc 8.2 3.4 28 73 25 33 H.M 12.3 4.1 24 78 25 35 N 
6 757 Yovaan 12/Mc 7.8 3.6 27 73 22 35 H.M 11.4 4.0 26 79 27 35 N 
7 30114 Valliappan 11/Mc 8.6 3.8 28 74 26 34 H.M 12.6 3.8 24 80 26 33 N 
8 33356 Ansu 12/Fc 8.7 3.5 27 77 24 32 H.M 11.2 3.4 24 78 27 34 HM 
9 30118 Maathavan 11/Mc 8.4 3.4 25 76 24 33 H.M 11.6 3.1 26 74 27 32 N 
10 33353 Jeyasheela 12/Fc 7.8 3.3 22 75 26 37 H.M 12.1 3.1 26 77 26 34 N 
11 30117 Sudalai 9/Mc 8.0 3.8 24 75 24 33 H.M 11.2 4.1 24 78 25 33 N 
12 33355 Parimala 12/Fc 9.0 2.8 26 76 25 36 H.M 11.8 4.1 28 79 27 31 N 
13 30120 Venmathi 7/Fc 7.6 3.6 24 74 22 38 H.M 11.6 3.8 27 78 25 34 N 
14 33354 Mano 12/Fc 8.1 3.5 28 75 23 34 H.M 10.8 3.6 28 77 26 34 N 
15 1064 Sheeba 10/Fc 8.6 3.8 27 76 24 35 H.M 11.4 3.9 26 75 28 33 N 
16 1065 Priya 10/Fc 8.3 3.8 24 78 24 36 H.M 12.6 3.3 27 73 25 34 N 
17 1066 Vennila 10/Fc 7.6 3.1 26 76 24 37 H.M 11.2 3.8 25 78 26 31 N 
18 1119 Prema 12/Fc 8.4 3.4 24 71 24 34 H.M 11.6 3.8 26 80 27 36 HM 
19 1120 Sangeetha 12/Fc 7.4 3.8 24 76 25 35 H.M 10.5 4.0 26 75 28 32 N 
20 1155 Mercy 12/Fc 7.8 2.9 26 74 24 32 H.M 11.2 3.4 24 76 25 35 N 
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INVESTIGATION RESULTS 
S.N
O 
IP. NO 
AGE 
/SEX 
BLOOD URINE MOTION 
BEFORE TREATMENT AFTER TREATEMENT BEFORE TREATMENT AFTER TREATEMENT 
BEFORE 
TREATMENT 
AFTER TREATEMENT 
T
C
 
C
E
L
L
S
 
C
O
L
U
M
N
 
DC ESR (mm) 
T
C
 
C
E
L
L
S
 
C
O
L
U
M
N
 
DC ESR (mm) 
A S D A S D 
OV
a c
y
st
 
OB 
Ov
a C
y
s
t OB 
P L E 
½ 
hr 
1 
hr 
P L E 
½ 
hr 
1 
hr 
1 256 2 /Fc 9600 59 39 2 6 10 8800 63 35 2 3 12 Nil Nil NAD Nil Nil NAD P P Nil Nil Nil Nil 
2 711 11/Fc 8300 57 36 7 7 15 8200 60 35 5 4 15 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
3 25764 10/Mc 9000 58 38 4 5 12 9000 60 37 3 5 14 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
4 755 12/Mc 9700 62 35 3 4 13 9800 64 34 2 2 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
5 756 12/Mc 9200 62 30 8 8 15 9000 62 34 4 4 11 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
6 757 12/Mc 9100 60 36 4 7 12 9200 62 35 3 3 15 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
7 30114 11/Mc 9200 58 38 4 7 11 9000 60 36 4 2 13 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
8 33356 12/Fc 9500 60 35 5 8 14 9600 63 36 2 3 14 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
9 30118 11/Mc 9200 65 33 2 9 13 9000 63 35 2 4 15 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
10 33353 12/Fc 8800 60 36 4 6 12 8800 62 35 2 3 12 Nil Nil NAD Nil Nil NAD P P Nil Nil Nil Nil 
11 30117 9/Mc 8500 60 38 2 8 15 8900 63 35 2 2 13 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
12 33355 12/Fc 9200 66 30 4 6 12 9000 60 38 2 5 14 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
13 30120 7/Fc 9000 60 36 4 9 13 9200 65 33 2 4 15 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
14 33354 12/Fc 9800 60 36 4 7 11 9700 58 38 4 5 15 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
15 1064 10/Fc 10200 52 45 3 9 15 9500 55 39 6 4 14 Nil Nil NAD Nil Nil NAD P P Nil Nil Nil Nil 
16 1065 10/Fc 9400 65 30 5 8 11 9600 63 33 4 5 13 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
17 1066 10/Fc 9000 62 35 3 8 16 9200 55 37 3 4 12 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
18 1119 12/Fc 8300 59 36 5 7 15 8500 59 37 4 5 15 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
19 1120 12/Fc 8700 60 35 5 6 14 9000 58 37 5 4 14 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
20 1155 12/Fc 8600 67 29 4 5 12 9000 60 38 2 3 15 Nil Nil NAD Nil Nil NAD Nil Nil Nil Nil Nil Nil 
 
TC – Total Count    L – Lymphocytes  S – Sugar   OB – Occult Blood 
DC – Differncial count   E – Eosinophil  D – Deposit   HM – Hypochromic Microcytic 
ESR – Erythrocyte sedimentation rate     P  - Present 
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OUT PATIENTS CASE RECORD 
 
Sl . No Op No Name Age/Sex 
No of days 
treated 
Remarks 
1 29829 Akash 9/Mc 49 Good 
2 35112 Guruparan 8/Mc 45 Good 
3 29830 Abilash 7/Mc 46 Good 
4 20638 Yoonush 11/Mc 48 Good 
5 26770 Harish 5/Mc 45 Good 
6 5179 Vengatesh 6/Mc 47 Good 
7 23442 Nanthini 6/Fc 49 Good 
8 5181 Renush 10/Mc 48 Good 
9 5178 Giftson 6/Mc 45 Fair 
10 5180 Kiruba 5/Fc 44 Fair 
11 26771 Namulesh 6/Fc 48 Good 
12 25786 Siva jothi meena 6/Fc 49 Good 
13 24467 Kirthigaraj 5/Fc 46 Fair 
14 24770 Nancy 6/Fc 47 Good 
15 26820 Isakkimuthu 6/Fc 46 Good 
16 15262 Harish Nithin 7/Mc 49 Good 
17 17184 Muhamed Shad 9/Mc 48 Good 
18 20107 Indhu 8/Fc 45 Good 
19 21499 Rosea paul 4/Mc 47 Good 
20 3265 Angeline 11/Fc 46 Good 
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DISCUSSION 
 
    Pandu is a clinical entity described and it has clinical features such as loss of 
appetite, lassitude, and emaciation, pallor of the mucus membrane like conjunctiva, 
tongue and nails, dyspnoea on exertion. These features are more or less equivalent to 
nutritional anemia  a clinical entity described in modern literatures.  
Selection of trial drug 
Biochemical Analysis 
    The results of Biochemical analysis of “Pandu Noikku Kalappu Thool” shows 
that it consists of Tannic acid, Reducing sugar, unsaturated compounds, amino acids  and 
ferrous iron. 
   The process of ferrous iron in Pandu noikku Kalappu Thool may help in 
hemoglobin synthesis in mild or chronic anemic patients, caused due to nutritional 
deficiency. 
Pharmacological Studies 
Clinical trail 
1. Incidence according to Paruvakaalam 
When the clinical trial of pandu noikku kalappu thool was performed 20 
outpatients and 20 in patients with Pandu were treated with this trial drug during the 
period of December 2015 to May 2016. Among the experimental period, however the 
Munpani kaalam shows the period for the out burst of this disease. 
2. Incidence according to Age 
In the present study both in the outpatient ward and inpatient ward the severe 
occurrence of Pandu Noi was noticed among the age group of 6 to 12 years and 
moderate occurrence of was noticed among the age group of 2 to 5 years.This does not 
mean that the occurrence is more common in children belonging to age group of 6 to 12 
years. One of the reason for this may be that the growth depends more amount of iron 
and nutrition than the normal adult. 
3. Incidence according to Sex 
          On the basis of the sex, the disease Pandu Noi affects both male and female 
children more or less equally, hence there is no sex predilection for Pandu. 
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4. Incidence according to Religion 
     Regarding the distribution of this disease on the basis of religion of the patients, 
47.5% were Hindus, 47.5% were Christians and 5% were muslim.So on the basis of this 
data, one cannot predict the occurrence of the Pandu Noi on the basis of regilion. 
5. Incidence according to Thinai 
Similarly the distribution of patients on the basis of thinai, shows that 12.5% of 
patients belong to Kurinji and 82.5% from Marutham and 5% from Neithal. Since in 
Siddha literature Marutha nilam is considered as a disease free zone. However the 
changing life style, dietary habits from their ancestor and environment, poor 
socioeconomic status also be one of the reasons for this occurrence. Further the high 
temperature in Palayamkottai and its surrounding areas may be responsible for 
increasing pitham and may result in increased occurrence of Pandu noi. 
6. Incidence according to Mukkuttra Kaalam 
Since the present study restricted to children below age of 12, all the patients 
belong to Vaatha kaalam only. So in the present study, it is inferred that in children 
Pandu Noi is a Pitha disease occurring in Vaathakaalam. 
7. Incidence according to Socioeconomic Status 
Regarding socioeconomic status of patients 80% were from families, 20% were 
from middle class families. Hence this observation supports the view that occurrence and 
spreading of Pandu Noi may be due to poor socioeconomic status of the patients. 
8. Diet 
In the present study, it is noticed that 75% of patients had mixed food habits, 
consuming both vegetarian and non-vegetarian diets and 25% had vegetarian diet. 
9. Incidents according to cases from same family 
The incidence of children have positive family history are 25% and negative 
family history are 75%. 
10.  Incidence according to Uyir thathukkal 
  Among the three vital forces, pitham is mainly affected. That too among the five 
types of pitham, Ranjagam is affected which causes discolouration of mucous 
membrane. Also other forms of Pitham, Analaham, Sathagam and Prasagam are affected 
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in 100% of the cases, the derangement of pitham is followed by derangement of 
Kaphamm and Vatham 
11. Incidence according to Ezhu udalkattukal 
Among seven Udal kattukal, Saaram and Senneer were affected in 100% of the 
cases. 
12. Incidence according to Envagai thervugal 
In this, the changes of naadi, sparisam, naa, niram, mozhi, vizhi, malam and 
moothiram were noted. 
NAADI 
   According to this study, vathakala naadi was found in 55% of cases, kabavatha 
naadi in 25% of cases and kabhapitham naadi in 20% of cases. 
SPARISAM 
   Palpable liver and spleen tenderness may be noted. Palpitation may be noted. The 
skin of the patient should also be noted. 
NAA 
   In all of the cases, the tongue was pallor in color. 
NIRAM 
  Due to involvement of Pitham, the body was pallor in  color. This condition was 
noted in almost all cases. 
MOZHI 
   Not affected in all cases. 
VIZHI 
In iron deficiency Anemia, Pallor of the conjunctiva was noted in almost all the 
cases. 
MALAM 
The color of the stools is pale yellow color. Among the 40 cases28 cases had 
constipation 
MOOTHIRAM 
In Pandu noi, due to increased pitham, the urine was yellow or dark yellow in color. 
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13. Incidence according to Prognosis Assessment and Efficacy of Trial drug 
Pandu noikku kalappu thool 
 
After conforming the diagnosis of types of Pandu, the patients were treated with 
“Pandu Noikku Kalappu Thool” with a dose of 500mg to 2 grams, thrice a day after 
meals with honey or ghee, depending on the age and body weight of the patients. The 
observation of signs and symptoms were followed as long as the patients in the hospital 
as inpatients. The prognosis were clearly recorded. When symptoms disappeared the 
patients were discharged by examination of the blood and other systemic signs and 
symptoms once again. It is clear that among 40 patients, who had been treated with 
Pandu noikku kalappu thool, 34 cases were good result, 6 cases were fair results. This 
showed that Pandu noikku kalappu thool had good effect in curing Pandu noi in 85% of 
patients and 15% of our trial, expressed moderate responses to Pandu noikku kalappu 
thool. 
 
      The aim of therapy is to increase the level of hemoglobin. As the trial drug has 
significant haematinic, stomachic and tonnic actions, the aim are attained. 
 
    During the treatment, iron rich diet was strictly advised. Along with the trial drug 
all the patients were advised to taken green leafy vegetables, fruits, meat, seafood, nuts, 
cereals and eggs because these are rich in iron content. 
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SUMMARY 
    Pandu noi (Anemia) is a disease affecting both male and female children as per 
the Siddha and Modern systems of Medicine. 
 
         To treat children with anemia, a Siddha trial drug, “Pandu noikku kalappu thool” 
has been prepared. The collection, confirmation, and purification of all ingredients have 
been described. The method of preparation of “Pandu noikku kalappu thool” has also 
been described. 
 
           The biochemical analysis of the trail drug shows the presence of aminoacids, 
Calcium, Ferrous iron, and Tannic acid the results have been tabulated. The 
pharmacological effects such as Haematimic, Laxative effects of trail drug have been 
studied and the results have been tabulated. 
 
     The trail drug, Pandu noikku kalappu thool has been used to treat 20 inpatients 
of children  both sexes affected by Pandu IPD ward of PG- Kuzhanthai Maruthuvam 
Department of GSMC. Maximum occurance of this disease was observed in school 
going children(6 to 12years). 
 
     Before treatment, the signs and symptoms for Pandu are noticed and confirmed 
by clinical analyses. During treatment, the dose of 500mg to 2 grams of Pandu noikku 
kalappu thool, thrice a day after meals, along with honey or ghee  has been given to 
children affected by Pandu noi depending on their age, body weight and severeness of 
the disease. 
 
   Findings reveal about the impact of the disease in the body. Statistical study of 
the details in the case sheet was observed and the results have a see through idea about 
the disease. 
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No adverse side effects were reported during or after the course of treatment. 
The drug selected for the study was found to be easily available drug, easily 
administered and also more effective against Pandu noi without any adverse side effects. 
 
The bio-chemical analysis and pharmacological study of the drug revealed its 
efficacy. From the studies, the drug Pandu Noikku Kalappu Thool possesses significant 
Haematinic action. 
  
By analyzing and taking into consideration of all these results, it is inferred that 
the Pandu Noikku Kalappu Thool has effective actions in controlling the Pandu Noi. 
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CONCLUSION 
 
Pandu Noikku Kalappu Thool has significant haematinic and laxative actions. 
  From the studies it is clear that Pandu noi, is caused by derangement of pitham, 
followed by the derangement of vatham and kabam. 
 
      It has shown very good result in controlling iron deficiency anemia and it raises 
the hemoglobin level in anemia patients when given regularly along with other healthy 
supplementary diets. 
 
     Both symptomatic relief and qualitative improvement were observed in the 
patients. It is also proved that it is effective treatment for nutritional deficiency anemia. 
No adverse effect were observed in the Pandu Noikku Kalappu Thool treated patients. 
 
The drug is a compound herbal product, easily available, cost effective, easy to 
administrate, simple way of preparation, high efficacy, harmless to infants and children. 
 
    The dose of the drug used in the present study is to be used in pediatric practice 
to treat children with Pandu noi. 
 
 This drug has Thuvarppu, Inippu, Kaippu tastes. These tastes correct the pitha 
diseases like pandu.  
 
 Ingridents of Pandu Noikku Kalappu Thool has ascorbic acid. This vitamin C 
enhances the Iron absorptions. 
 
    Because of these encouraging outcoming results, the study may be undertaken 
with same medicine in a large number of cases and it may open new windows for the 
treatment of “Pandu Noi” 
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BIO-CHEMICAL ANALYSIS OF PANDU NOIKKU KALAPPU THOOL 
Preparation of the extract:  
 5gms of the drug was weighed accurately and placed in a 250ml clean beaker 
then 50ml of distilled water is added and dissolved well. Then it is boiled well for about 
10 minutes. It is cooled and filtered in a 100ml volumetric flask and then it is making up 
to 100ml with distilled water.  This fluid is taken for analysis. 
QUALITATIVE ANALYSIS 
S.NO EXPERIMENT OBSERVATION INFERENCE 
1.  TEST FOR CALCIUM 
2ml of the above prepared extract is taken 
in a clean test tube. To this add 2ml of 4% 
Ammonium oxalate solution 
A white precipitate is 
formed 
Indicates the 
presence of 
Calcium 
2. TEST FOR SULPHATE 
2ml of the extract is added to 5% Barium 
chloride solution. 
No white precipitate 
is formed 
Absence of 
Sulphate 
3.  TEST FOR CHLORIDE 
The extract is treated with silver nitrate 
solution 
No white precipitate 
is formed 
Absence of 
Chloride 
4. TEST FOR CARBONATE 
The substance is treated with 
concentrated Hcl. 
No brisk 
effervescence is 
formed 
Absence of 
Carbonate 
5. TEST FOR STARCH 
The extract is added with weak iodine 
solution 
Blue colour is 
formed 
Indicates the 
presence of 
Starch 
6.  TEST FOR FERRIC IRON 
The extract is acidified with Glacial 
acetic acid and potassium ferro cyanide. 
No blue colour is 
formed 
Absence of ferric 
Iron 
7. TEST FOR FERROUS IRON  
The extract is treated with concentrated 
Nitric acid and Ammonium thiocyanate 
solution 
Blood red colour is 
formed 
Indicates the 
presence of 
Ferrous Iron 
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8.  TEST FOR PHOSPHATE 
The extract is treated with Ammonium 
Molybdate and concentrated nitric acid 
No yellow 
precipitate is formed 
Absence of 
Phosphate 
9.  TEST FOR ALBUMIN 
The extract is treated with Esbach’s 
reagent 
No yellow 
precipitate is formed 
Absence of 
Albumin 
10.  TEST FOR TANNIC ACID 
The extract is treated with ferric chloride. 
Blue black 
precipitate is formed 
Indicates the 
presence of 
Tannic acid 
11.  TEST FOR UNSATURATION 
Potassium permanganate solution is 
added to the extract 
It gets decolourised 
Indicates the 
presence of 
Unsaturated 
compounds 
12.  TEST FOR THE REDUCING SUGAR 
5ml of Benedict’s qualitative solution is 
taken in a test tube and allowed to boil for 
2 minutes and add 8-10 drops of the 
extract and again boil it for 2 minutes. 
Colour change 
occurs 
Indicates the 
presence of 
Reducing sugar 
13.  TEST FOR AMINO ACID 
One or two drops of the extract is placed 
on a filter paper and dried well. After 
drying, 1% Ninhydrin is sprayed over the 
same and dried it well. 
Violet colour is 
formed 
Indicates the 
presence of 
amino acid 
14. TEST FOR ZINC 
The extract is treated with Potassium 
Ferrocyanide. 
No white precipitate 
is formed 
Absence of Zinc 
 
Inference: 
 The given sample of “Pandu noikku kalappu thool” contains Calcium, Starch, 
Ferrous iron, Tannic acid, Unsaturated compounds, Reducing sugar and Amino acid. 
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HAEMATINIC ACTIVITY OF  SIDDHA FORMULATION PANDU NOIKKU 
KALAPPU THOOL IN PHENYLHYDRAZINE INDUCED ANAEMIC RATS 
 
INTRODUCTION 
Iron is the main component of Haemoglobin which is responsible for transporting 
oxygen, myoglobin in muscles and part of many enzymes which are involved in cellular 
processes, respiration and cell division. Anaemia is defined as the reduction of 
haemoglobin below the normal limit and is the most common disorder of the blood. 
They are usually due to iron deficiency. Recently, the World Health Organization 
estimated that anaemia affects one-quarter of the world's population and is 
concentrated within preschool age children and women1. Iron deficiency affects a 
significant part, and often a majority, of the population in nearly every country in the 
world2. Iron deficiency is estimated to be the most common cause of anaemia   
worldwide and is particularly prevalent in developing nations in Africa and Asia3. 
Prevalence of anaemia in all the groups is higher in India as compared to other 
developing countries4.  It has serious consequences for the health and well-being as well 
as social and economic impacts of India. Untreated iron deficiency anaemia can become 
severe enough to interfere with daily life. From the above scenario, we are in a critical 
need to control anaemia. In this connection, a search for cheap, easily available and 
efficacious haematinic drugs in the modern world is going on. Drugs from the plant 
material are generally believed to be more effective and having fewer side effects 
compared to modern synthetic medicines. Knowledge of iron deficiency and its 
treatment in Siddha System of medicine dates back from time immortal. Many plants in  
Siddha  system of  medicine are  known  to  have remarkable effects in treating 
anaemia. 
 
In view of the many health benefits of siddha formulation pandu noikku kalappu 
thool, we propose to study the haematinic activity of the trial drug siddha formulation 
pandu noikku kalappu thool in phenylhydrazine induced anaemic rats which may serve 
as a beacon light in treating anaemia. 
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MATERIALS AND METHODS 
Animals 
Albino rats of either sex weighing about 150-180 g were obtained from animal 
house of department of pharmacology, K.M.College of pharmacy, Madurai, India. The 
rats were acclimated to standard laboratory conditions (temperature: 25± 2ºC) and 
maintained on 12 h light/dark cycle. All the rats were provided with standard food and 
free access to water ad libitum. This present study was approved by the Institutional 
animal ethical committee (IAEC). 
 
Evaluation of Haematinic Activity 
Phenylhydrazine (PHZ) induced anaemia model was used to evaluate the 
haematinic effects of siddha formulation pandu noikku kalappu thool in rats(5,6). 
Animals were divided in to f i v e  groups of 6  each.  The first group considered as a 
normal control group and received distilled water. Except normal control group (Group 
1), all the other groups were administered phenylhydrazine (10 mg/kg b.w) by oral 
administration daily for seven days to reduce the concentration of haemoglobin. Rats 
were considered as anaemic model if haemoglobin concentration was less than 12 
g/dl(7). Anaemic rats were then randomly grouped in to four. The second group was 
kept as an anaemic control received 2 % of CMC only. The third, fourth groups were 
administered with test drug siddha formulation pandu noikku kalappu thool at single oral 
doses of 200 mg and 400 mg respectively. The fifth group was kept as standard group 
received Standard haematinic syrup (2 ml/kg p.o). All the drugs, distilled water and 
vehicle were administered up to 2 weeks. 
 
Haematological investigation 
Blood was collected from the animals from initial phase (pre- treatment), after 
one week and two weeks (during and post- treatment) by puncture of retro-orbital vein. 
To analyse the haematinic  potential  of  siddha formulation pandu noikku kalappu thool 
with  different  doses  and standard drug, the haematological parameters were assessed 
which include Hb concentration, Packed Cell Volume (PCV), Total Red Blood Cells 
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(TRBC), MCV (Mean corpuscle volume), MCH (Mean Cell Haemoglobin) and MCHC 
(mean corpuscular haemoglobin concentration) and compared with normal control and 
anaemic control(8). 
 
Statistical analysis 
Results of the present study were statistically analysed and expressed as mean ± SEM 
by using One-Way ANOVA followed by Newmann keuls mul tiple range tests . 
*P < 0.05; 
**P < 0.01 when compared to normal and anaemic control groups 
 
RESULTS AND DISCUSSION 
Phenylhydrazine is used for the induction of haemolytic anaemia and the study 
of its mechanism in many species including rats(9,10). Phenyl free radical produced via 
the 2- electron oxidation of phenylhydrazine by oxyhemoglobin. This free radical binds 
with red cell and hemolyzes it rapidly and converts oxyhemoglobin into methemoglobin.  
Thus, PHZ-induced haemolytic injury seems to be derived from oxidative alterations to 
red blood cell proteins rather than to membrane lipids(11).The RBC, Hb, and PCV of 
rats administered Phenylhydrazine decreased significantly (P < 0.01) while the MCV 
and MCH increased giving rise to macrocytic anaemia (P < 0.05). pandu noikku kalappu 
thool at the dose of 200 and 400mg/kg showed good percentage of improving in 
haemoglobin level, which was almost equivalent to standard treated group indicating   
correction   of   anaemia   induced   by   Phenyl hydrazine after 14 days treatment. 
Treatment with pandu noikku kalappu thool at the dose of 200 and 400mg/kg for 14 day 
is represented in Table 1. Significant increase in Hb (p < 0.01) was observed when 
compared to positive control and it was comparable to standard drug used in this study. 
Phenylhydrazine altered the haematological parameters by haemolysis characterized by 
decrease in haemoglobin concentration, total RBC counts and PCV on day 7. However, 
the haematological parameters were restored to normal range after treatment with 
pandu noikku kalappu thool at the dose of 200 and 400mg/kg for 14 days. Effective 
changes were observed after one week of treatment of anaemic rats with pandu noikku 
kalappu thool at the dose of 200 and 400mg/kg reversed the influence of 
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Phenylhydrazine resulting to a significant (P < 0.05) increase in RBC, Hb, and PCV. The 
Hb, RBC and PCV reached near normal at the second week of the treatment. Rats treated 
with Phenylhydrazine (10 mg/kg/day for 7 days) resulted in a marked haemolytic 
anaemia characterised by decreased RBC, Hb and PCV. The main function of the RBC is 
the transportation of oxygen in to the tissues of the body. At such, any pathological or 
physiological condition that affects the RBC alters its function and this may be 
detrimental to the body. In this study Phenylhydrazine altered the function of RBC by 
haemolysis characterised by decreased levels of RBC, Hb and PCV. However, this effect 
was restored after one week of pandu noikku kalappu thool at the dose of 200 and 
400mg/kg treatment. Also the recovery was progressive such that after 1 week of 
continuous treatment, the Hb concentration and PCV were higher in the treated groups 
than in the normal control group. 
 
CONCLUSION 
In order to provide effective, safe and cheap drug and to prove the traditional 
claim for the treatment of anaemic conditions, the pandu noikku kalappu thool at the 
dose of 200 and 400mg/kg was evaluated and found significantly increased the Hb, 
haematocrit and RBC count in anaemic rats indicating the haematinic effect. Haematinic 
effect was more pronounced in ELC 200 which showed its dose-dependent activity. The 
rapid and progressive recovery of anaemic rats responding to treatment of pandu noikku 
kalappu thool at the dose of 200 and 400mg/kg may be due to increased erythropoiesis. 
However, the mechanism of action by which pandu noikku kalappu thool at the dose of 
200 and 400mg/kg produced its effect on increasing RBC, Hb and PCV in experimental 
animals need to be evaluated in a detailed scientific manner and also conducting clinical 
trials which are required to understand the exact  molecular mechanism of action.  
Based  on  the result  in  can  be concluded that  the pandu noikku kalappu thool at the 
dose of 200 and 400mg/kg is a good drug of choice for the anaemia. 
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 Table :1. Hematological Parameters of Rats after 14 Days Treatment with pandu 
noikku kalappu thool 
 
Para meters Group 1 
(Normal) 
Group 2 
(Anaemic 
Control) 
Group 3 
(200MG/KG 
mg/kg) 
Group 4 
(400 mg/kg) 
Group 5 
(Heamatinic 
syrup) 
Hb (g/dl) 
 
18.45 ± 
1.32** 
9.00 ± 1.12 20.01 ± 
0.74** 
20.18 ± 
0.80** 
22.10 ± 1.88** 
PCV (%) 47.38 ± 1.10 44.11 ± 1.30 44.08 ± 2.4 42.10 ± 2.2 52.02 ± 1.46* 
RBC 
(x106/ml) 
4.22 ± 0.24 4.84 ± 0.30 4.86 ± 0.33 4.78 ± 0.28 5.10 ± 0.28 
MCV (fl) 78.38 ± 
2.12** 
90.56 ± 2.42 82.26 ± 2.21* 78.31 ± 
1.72** 
74.52 ± 2.21** 
MCH (pg) 25.78 ± 2.64 33.12 ± 2.17 31.24 ± 1.96 29.86 ± 1.82 28.10 ± 2.53 
MCHC (g/dl) 32.26 ± 1.11 33.15 ± 1.20 33.19 ± 1.23 33.52 ± 0.65 34.17 ± 2.20 
 
Values are mean ± S.E.M. (Newmann keuls test). *P<0.05; **P<0.01Vs Control N = 6 
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LAXATIVE ACTIVITY OF SIDDHA FORMULATION PANDU NOIKKU 
KALAPPU THOOL IN EXPERIMENTAL ANIMALS 
 
INTRODUCTION 
Plant and plant products are being used as a source of medicine since long. 
According to the World Health Organization, more than 80% of the world's population, 
mostly in poor and less developed countries depends on traditional plant-based medicines 
for their primary health care needs [1]. The present study was intended to evaluate the 
laxative activity of the siddha formulation pandu noikku kalappu thool. 
 
MATERIALS AND METHODS 
Animals 
Male Wistar Albino rats weighing between 150– 220 g were used for the study. 
The animals were obtained from animal house of K.M College of Pharmacy, Madurai, 
India. On arrival the animals were placed at random and allocated to treatment groups in 
polypropylene cages with paddy husk as bedding. Animals were housed at a temperature 
of 24 ± 2oC and relative humidity of 30–70 %. A 12:12 light: dark cycle was followed. 
All animals were allowed free access to water and fed with standard commercial pelleted 
rat chaw (Hindustan Lever Ltd, Mumbai).  All the experimental procedures and protocols 
used in this study were reviewed by the Institutional Animal Ethics Committee 
(661/02/c/CPCSEA) and were in accordance with the guidelines of the CPCSEA. 
  
LAXATIVE ACTIVITY [2] 
Rats fasted for 12 h before the experiment, were placed individually in cages lined 
with clean filter paper. The animals were divided in to 4 groups of 6 rats in each group. 
Group I, served as control received saline (10 ml/kg, p. o.), Group II served as reference 
control received sodium picosulfate (5mg/kg, p.o) and groups III and IV received 200 
and 400 mg/kg of siddha formulation pandu noikku kalappu thool extract respectively 
through oral administration. The total weight of normal as well as wet faeces production 
in all 4 groups was monitored for 16 h. 
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STATISTICAL ANALYSIS 
Results were expressed as mean ± SEM. The data were analyzed by using one 
way analysis of variance (ANOVA) followed by Newmann keul‟s  multiple range tests. P 
values < 0.05 were considered as significant. 
 
RESULTS 
The siddha formulation pandu noikku kalappu thool was studied for its laxative 
activity in Wistar Albino rats. The laxative activity was assessed by measuring the wet 
faeces in all test drug administered groups. The siddha formulation pandu noikku kalappu 
thool  showed significant (P<0.001) dose dependent laxative activity as compare to 
normal control animals. The laxative activity produced by the siddha formulation pandu 
noikku kalappu thool was similar to that of the reference control sodium picosulfate. The 
laxative activity of siddha formulation pandu noikku kalappu thool was studied in rats. 
The results showed that an oral administration of the siddha formulation pandu noikku 
kalappu thool produced significant and dose dependant increase in faeces output of rats. 
Sodium picosulfate is a member of the poly phenolic group of stimulant laxatives. 
Following oral administration, it is converted in the colon to an active form through the 
action of bacterial enzymes[3]. As a result, its effects are directed the colon, where it 
stimulates peristalsis and, in common with other laxatives,reduces water reabsorption 
leading to the softening of stools. The results suggest that the siddha formulation pandu 
noikku kalappu thool might also be produced its laxative activity by reducing the water 
reabsorption in the colon which might soften the stool. 
 
DISCUSSION 
The laxative activity of siddha formulation pandu noikku kalappu thool was 
studied in rats. The results showed that an oral administration of the siddha formulation 
pandu noikku kalappu thool produced significant and dose dependant increase in faeces 
output of rats. Sodium picosulfate is a member of the poly phenolic group of stimulant 
laxatives. Following oral administration, it is converted in the colon to an active form 
through the action of bacterial enzymes [3]. As a result, its effects are directed the colon, 
where it stimulates peristalsis and, in common with other laxatives,reduces water 
reabsorption leading to the softening of stools. The results suggest that the siddha 
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formulation pandu noikku kalappu thool might also be produced its laxative activity by 
reducing the water reabsorption in the colon which might soften the stool. 
 
CONCLUSION 
From the result it could be concluded that oral administration of siddha 
formulation pandu noikku kalappu thool shows significant laxative activity in rats. 
Further phyto-chemical studies are required to isolate the active compounds responsible 
for laxative activity which could be a major contribution to prove the claims in Indian 
systems of medicine. 
 
Table I: Laxative activity of siddha formulation pandu noikku kalappu thool in rats. 
GROUPS DRUG TREATMENT FAECES OUTPUT (gms) 
I Control Saline (10ml/kg) 3.60±0.30 
II Sodium picosulfate 
(5mg/kg) 
12.05±1.12*** 
III pandu noikku kalappu thool 
200mg/kg 
10.35±0.90*** 
IV pandu noikku kalappu thool 
400mg/kg 
11.55±0.96*** 
Values are in Mean ± SEM; (n = 6); *P < 0.05, 
**P < 0.01, *** P < 0.001 Vs Control 
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EVALUATION OF HEPATOPROTECTIVE ACTIVITY OF SIDDHA 
FORMULATION PANDU NOIKKU KALAPPU THOOL 
 
In traditional medicines, various herbal preparations are being used for treating 
liver disorders. In the absence of an effective treatment in modern medicine, efforts are 
being made to find out suitable herbal drugs.In previous work we have reported the on 
activity of moringa oleifera (1), Caseria ecsulenta (2) and Orthosiphon thymiflorus (3) 
against paracetamol induced hepatotoxicity. The present study was taken up to evaluate 
the effects of siddha formulation pandu noikku kalappu thool against Isoniazid and 
Rifampicin induced hepatotoxicity.    
 
Methods:- 
Animals and treatment: 
Male wistar rats (180-200 gm) were supplied by experimental animal centre, 
KMCP. Throughout the study, rats were housed in temperature – controlled rooms with 
12h light – dark cycle, and were free access to food and water. 
 
For hepatotoxicity model, 100 mg/kg per day of INH and RIF each was used in 
the study(4)  INH and RIF solution were prepared separately in sterile distilled water. 
Rats were treated with INH, co-administered with RIF for 21 days. For the 
hepatoprotective model, 200 mg/kg per day of siddha formulation pandu noikku kalappu 
thool  and 400 mg/kg siddha formulation pandu noikku kalappu thool  along with 
INH+RIF solution was administered. 
 
Treatment protocol: 
Group I : Normal control the animals were given normal saline only. 
Group II : Hepatotoxicity control the animals were given INH+RIF for 21 
                          days. 
Group III : Standard group  the animals were given 
  INH+RIF+SILYMARIN  orally for 21 days. 
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Group IV : Treatment group the animals were given INH+RIF+ siddha formulation 
pandu noikku kalappu thool  (200 mg/kg orally for 21 days). 
Group V : Treatment group  the animals were given INH+RIF+ siddha formulation pandu 
noikku kalappu thool  (400 mg/kg) for 21 days). 
 
Method: 
Rats were treated as per the treatment protocol. The protocol was approved by the 
institute‟s animal ethical committee. In the present study hepatoprotective activity was 
evaluated biochemically. On day 21 the rats were anaesthetized and sacrificed 1 h after 
administration drug. The blood was collected by retro-orbital plexus method; the serum 
was separated by centrifugation and used for the estimation of 
1. Serum alkaline phosphatase,ALP.  
2. Serum AST (S.G.O.T). 
3. Serum ALT (S.G.P.T). 
4. Total protein and Albumin. 
5. Serum cholesterol. 
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Table No.1 
EFFECT OF SIDDHA FORMULATION PANDU NOIKKU KALAPPU THOOL 
ON SERUM ENZYMES 
 
 TOTAL 
PROTEIN 
(g%) 
ALBUMIN 
(g/dl) 
TOTAL 
CHOLESTEROL 
(mg/dl) 
ALT 
(u/l) 
AST 
(u/l) 
ALP 
(mg%) 
 
G1 
 
8.14±0.47 
 
4.91±0.35 
 
80.61±4.39 
 
75.38±3.50 
 
145.07±4.40 
 
120.39±4.02 
 
G2 
 
4.24±0.20**a 
 
2.12±0.22**a 
 
158.11±8.17**a 
 
176.14±8.88**a 
 
254.23±8.69**a 
 
307.59±6.49**a 
 
G3 
 
7.84±0.75**b 
 
4.54±0.34**b 
 
96.43±6.09**b 
 
83.03±5.82**b 
 
175.08±6.53**b 
 
203.96±5.42**b 
 
G4 
 
6.79±0.35*b 
 
3.95±0.33**b 
 
114.12±7.12**b 
 
123.03±6.01**b 
 
210.09±7.39**b 
 
264.77±6.03**b 
 
G5 
 
7.32±0.45**b 
 
4.28±0.37**b 
 
107.04±5.01**b 
 
103.61±5.70**b 
 
196.16±9.41**b 
 
258.89±6.75*b 
 
All values are expressed as Mean ± SEM for 6 animals in each group. 
G1-Normal Control 
G2-Toxic Control 
G3-Standard Control 
G4-Treatment Control, siddha formulation pandu noikku kalappu thool 
(200mg/kg) 
G5-Treatment Control, siddha formulation pandu noikku kalappu thool 
(400mg/kg) 
**a-values are significantly different from control (G1) (P<0.001), 
**b-values are significantly different from toxic control (G2) P<0.001 
All values are found out by using one way ANOVA followed by Newman Keul‟s 
multiple range tests.  
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RESULT 
 The present study has been attempted to demonstrate the role of hepatoprotective 
activity of siddha formulation pandu noikku kalappu thool in INH, Rifampicin induced 
hepatotoxicity at different doses. The results of hepatoprotective activity of  siddha 
formulation pandu noikku kalappu thool at the dose of 200mg/kg b.wt. and 400 mg/kg on 
rats intoxicated with INH, Rifampicin were illustrated in Table.1. 
Control group: G1 (Table 1) 
The basal level of liver enzymes [ALP, AST, ALT] in control were 120.39 ± 4.02, 
145.07 ± 4.40, 75.38 ± 3.50 respectively. Total protein and albumin levels were 8.14 ± 
0.47, 4.91 ± 0.35 respectively. The total cholesterol in the normal control were 80.61 ± 
4.39. 
Toxic control: G2 (Table 1) 
 INH and Rifampicin administration for 21 drugs resulted in increased level of 
cholesterol (158.11 ±8.17), accompanied by significant decrease in level of total protein 
(4.24 ± 0.20), total albumin (2.12 ± 0.22) and also significant increase in ALP (307.59 ± 
6.49), ALT(176.14±8.88),AST(254.23±8.69) as compared to the control. 
Treatment control: G3 (Table 1) 
There was significant decrease in cholesterol (96.43 ± 6.09), accompanied by 
significant increase in level of total protein (7.84 ± 0.75) total albumin level (4.54 ± 0.34) 
and also significant decrease in ALP (203.96 ± 5.42), AST (175.08 ± 6.53), ALT (83.03 
± 5.82) as compared to the toxic control. 
siddha formulation pandu noikku kalappu thool   groups: G4 (Table 1) 
 There was significant decrease in cholesterol (114.12 ± 7.12), accompanied by 
significant increase in level of total protein (6.79 ± 0.35), total albumin (3.95 ± 0.33) and 
also significant decrease in ALP (264.77 ± 6.33), AST (210.09 ± 7.39), ALT (123.03 ± 
6.01) as compared to the toxic control.  
siddha formulation pandu noikku kalappu thool groups: G5 (Table 1) 
 There was significant decrease in cholesterol (107.04 ± 5.01), accompanied by 
significant increase in level of total protein (7.32 ± 0.45), total albumin (4.28 ± 0.37) and 
also significant decrease in ALP (258.89 ± 6.75), AST (196.16 ± 9.41), ALT (103.61 ± 
5.70) as compared to the toxic control. 
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DISCUSSION: 
 Liver is the important organ actively involved in many metabolic functions and is 
the frequent target for a number of toxicants. Hydrazine is a known hepatotoxin. 
Antitubercular drug induced hepatotoxicity is an important and commonly encountered 
adverse effect (5,6). Incidence of hepatotoxicity is 1.2% with INH alone and increase to 
8-10%. When it‟s combined with Rifampicin(7). If this hepatotoxicity is not 
recognosized, it can be fatal. 
 During metabolism of INH, hydrazine can be produced both directly (from INH) 
and indirectly from acetyl hydrazine. 
Isoniazide metabolite, acetyl hydrazine and hydrazine have been implicated as the 
causative hepatotoxins. Oxidative activation of these metabolites in liver by cytochrome 
P450 (cyto P450) monooxygenase and free radicals which are capable of causing liver 
injury in animals (8, 9). Thus cyto P450 enzymes are critical in hepatotoxicity that leads 
to reactive, toxic metabolites. 
Rifampicin is a power inducer of mixed function oxidase contributes to 
hepatotoxicity of INH by enhancing the production of toxic metabolites.It is becoming 
increasingly apparent that many reactive intermediate formed during isoniazid 
metabolites are free radicals(10,11,12).The combination of INH and RIF was reported to 
result in a higher rate of inhibition of biliary secretion and a increase in liver cell lipid 
peroxidation and cytochrome P450 was thought to be involved  in the synergistic effect 
of RIF on INH.(13) . 
In this study it was noted that the administration of INH, Rifampicin decreased 
the level of total protein, albumin and increased the level of liver enzymes AST, ALT, 
ALP and TC. These parameters were brought back to the near normal level in Group 4 
and Group 5 treated with siddha formulation pandu noikku kalappu thool. Treatment with 
siddha formulation pandu noikku kalappu thool showed a protection against injuries due 
to the effect of INH, Rifampicin that may result from the interference with CYP450, 
resulting in the hindrance of formulation of hepatotoxic free radical. Attainment of near 
normal values of AST, ALT, ALP levels in INH and Rifampicin intoxicated animal 
groups with siddha formulation pandu noikku kalappu thool treated animals confirms the 
hepatoprotective activity.  
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The results of biochemical parameters supports the hepatoprotective activity of 
siddha formulation pandu noikku kalappu thool. 
 
CONCLUSION: 
In the present study, siddha formulation pandu noikku kalappu thool exhibit 
strong hepato protective activity, afforded protection from INH, Rifampicin induced liver 
damage. Hepato protective activity of siddha formulation pandu noikku kalappu thool 
may be due to free radical scavenging activity due to presence of Flavonoids and 
antioxidants. Additional studies are needed to better understand the mechanism of 
action of siddha formulation pandu noikku kalappu thool that is responsible for hepato 
protective. 
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murpdh; rpj;j kUj;Jtf; fy;Y}hp 
ghisaq;Nfhl;il 
 
            ghz;L Neha;f;F fyg;Gj; J}s; ghpfhpg;Gj; jpwid fz;lwpAk; kUj;Jt Ma;T 
xg;Gjy; gbtk; Ma;thsuhy; rhd;wspf;fg;gl;lJ. 
 
           ehd; ,e;j kUj;Jt Ma;T Fwpj;j midj;J tpguq;fisAk; Nehahspapd; 
ngw;NwhUf;F GhpAk; tifapy; vLj;Jiuj;Njd; vd cWjpaspf;fpNwd;. 
Njjp                                                             ifnahg;gk; 
,lk;                                                             ngah; 
                            
Nehahspapd; ngw;Nwhh; xg;Gjy; gbtk; 
           vd;dplk; ,e;j kUj;Jt Ma;tpd; fhuzj;ijAk; kUe;jpd; jd;ik kw;Wk; 
kUj;Jt topKiwg; gw;wpAk;  ,e;j kUj;Jtj;ijj; njhlhe;J vdJ Foe;ijapd; cly;  
,af;fj;ijf; fz;fhzpf;fTk; mjid fz;fhzpf;f gad;gLk;  kUj;Jt  Ma;Tf;$l 
ghpNrhjidfs; gw;wpAk; jpUg;jp mspf;Fk; tifapy; Ma;T kUj;Jtuhy; tpsf;fpf; 
$wg;gl;lJ. 
 
           ehd; ,e;j kUj;Jt Ma;tpd; NghJ fhuzk; vJTk; $whky; vg;NghJ 
Ntz;LkhdhYk; vd; Foe;ijia  tpLtpj;Jf;  nfhs;Sk;  chpikia 
njhpe;jpUf;fpNwd; 
 
          ehd; vd;Dila Rje;jpukhf Njh;T nra;Ak; chpikiaf; nfhz;L ghz;L 
Neha;f;fhd kUe;J ghz;L Neha;f;F fyg;Gj; J}s;  ghpfhpg;Gj; jpwid  fz;lwpAk;  
kUj;Jt  Ma;tpw;F vdJ Foe;ijia  cl;gLj;j  xg;Gjy;  mspf;fpNwd;. 
 
Njjp                                             ngw;Nwhh; ngah;  : 
,lk;                                             ifnahg;gk;      : 
                                                    rhl;rp ngah;     : 
                                                    ifnahg;gk;     : 
                                                    cwTKiw       : 
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for the management of Pandu( Anemia) 
CERTIFICATE BY INVESTIGATOR 
             I certify that I have disclosed all the details about the study in the terms readily 
understood by the parent 
Date………………..                            Signature……………………. 
Place……………….                            Name……………………….... 
CONSENT OF INFORMANT    
          I have  been informed to my  satisfaction,  by  the attending  physician , the  purpose  of  
the clinical trial, and  the nature of  the drug treatment  and follow –up    including  the  laboratory   
investigations  to  be  performed  to monitor  and    safeguard   my Son / Daughter   body  
functions.  
          I am aware of my right to opt out of the trial at any time during the course of the trial 
without having to give the reasons for doing so 
          I am exercising  my  free power  of  choice ;  hereby  give  my  consent   to be  included  as 
a  subject   in the  procedure  of   “Pandu noikku kalappu thool”   for the treatment of Pandu( 
Anemia) 
Date  :                                           Informant signature…………………….. 
Place:                                            Informant name………………………… 
Signature of witness                     Patient  Name……………………………                                                      
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GOVT. SIDDHA MEDICAL COLLEGE AND HOSPITAL 
DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI – 627 002 
 
CASE SHEET PROFORMA – PANDU NOI 
Name of the medical unit :                                 Nationality 
I.P.No                               :                                 Religion 
Bed. No                            :                                 Date of Admission  : 
Name                                :                                 Date  of Discharge  : 
Age / Sex                          :                                 Duration of treatment : 
Occupation ( Parents )      :                                 Diagnosis                   : 
Income  (Parents )             :                                 Medical officer         : 
Informant                          : 
Address                             : 
 Complaints and duration   : 
History of present illness   : 
History of past illness        : 
Antenatal History             : 
Birth and neonatal History : 
Dieteric and Nutritional History  : 
Developmental History     : 
Family History                 : 
Social History                   : 
Immunization History      : 
 
General examination   
1. Consciousness     : 
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2. Decubitus             : 
3. Anemia                 : 
4. Jaundice               : 
5. Cyanosis               : 
6. Clubbing              : 
7. Pedal edema         : 
8. Lymphadenopathy : 
9. Nourishment          : 
10. Skin changes         : 
Vital Sings 
1. Pulse             
2. B.P 
3. RR 
4. Temperature 
Anthropometry 
1. Height                  : 
2. Weight                 : 
3. Mid arm circumference : 
4. Head circumference      : 
5. Chest                             : 
6. Skin fold  thickness       : 
Siddha system – Clinical Examination 
 
Nilam 
Kurinchi 
Mullai 
Marutham 
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Neithal 
Palai 
Paruva Kaalam 
Kar 
Koothir 
Munpani 
Pinpani 
Elavenil 
Muthuvenil 
 
 
Pira Uruppugalin Nilai 
Moolai 
Iruthayam 
Puppusam 
Kalleeral 
Manneeral 
Kudal 
Siruneeragam 
Kuri 
Mummalam 
Viyarvai 
Malam 
Moothiram 
 
Mukkutra Udal 
Vaatha thegi 
Piththa thegi 
Kabha thegi 
Thontha thegi 
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Udal Kattugal 
Saaram 
Senneer 
Oon 
Kozhuppu 
Enbu 
Moolai 
Sukkilam/Suronitham 
Envagai Thervugal 
Naadi 
Sparisam 
Naa 
Niram 
Mozhi 
Vizhi 
Malam 
Moothiram 
 
Vatham 
Piranan 
Abanan 
Uthaanan 
Viyaanan 
Samaanan 
Naagan 
Koorman 
Kirugaran 
Devathathan 
Dhananjeyan 
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Pitham 
Analagam 
Ranjagam 
Sathagam 
Alosagam 
Pirasagam 
Kabam 
Avalambagam 
Kilethagam 
Pothagam 
Tharpagam 
Santhigam 
Neerkuri 
Niram 
Manam 
Nurai 
Edai 
Enjal 
Neikuri 
 
Malakuri 
Niram 
Nurai 
Elagal 
Erugal 
Modern Aspects 
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Systemic examination 
Cardiovascular system 
1. Inspection 
2. Palpation 
3. Percussion 
4. Auscultation 
Examination of other systems 
Respiratory system 
Abdomen 
Central nervous system 
Excretory system 
Lab Investigations 
1. Blood 
TC 
DC 
ESR 
Hb 
PCV 
MCV 
MCH 
MCHC 
Total RBC count 
Peripheral blood smear 
2. Urine 
Albumin  
Sugar 
Deposits 
Bile salts 
Bile pigments 
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3. Motion 
Ova 
Cyst 
Occult blood 
 
 
DIFFERENTIAL DIAGNOSIS 
PROGNOSIS 
MARUTHUVAMURAI 
ADVICE 
DAILY PROGRESS 
                Date           Symptoms               Medicine 
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GOVT. SIDDHA MEDIACAL COLLEGE AND HOSPITAL 
POST GRADUATE  -  BRANCH 
DEPARTMENT OF KUZHANTHAI MARUTHUVAM 
PALAYAMKOTTAI – 627 002 
 
ADMISSION – DISCHARGE SHEET 
Name of the medical unit :                             Nationality             :        
I.P. NO                             :                              Religion                : 
Bed No                             :                              Informant              : 
Name                                :                              Date of admission : 
Age / Sex                          :                              Date of discharge  : 
Occupation (parents)        :                              No of days treated : 
Income (parents)              :                               Diagnosis             : 
S.No Clinical  Features 
During 
admission 
During 
discharge 
     1. Pallor of conjunctiva and 
nail beds 
  
     2. Anorexia   
     3. Ulceration of mouth   
     4. Diarrhoea   
     5. Lassitude   
     6. Emaciation   
     7. Palpitation   
     8. Dyspnoea on exertion   
     9. Worm infestation   
 
Place : 
Date  :                                                          Signature of the medical officer 
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